<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Statins: Actions, side effects, and administration</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Statins: Actions, side effects, and administration</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Statins: Actions, side effects, and administration</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert S Rosenson, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mason W Freeman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sara Swenson, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 22, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Lipid-altering agents encompass several classes of drugs that include hydroxymethylglutaryl (HMG) CoA reductase inhibitors or statins, fibric acid derivatives, bile acid sequestrants, cholesterol absorption inhibitors, and nicotinic acid. These drugs differ with respect to mechanism of action and to the degree and type of lipid lowering. Thus, the indications for a particular drug are influenced by the underlying lipid abnormality. Conventional dosing regimens and common adverse reactions are described in a table  (<a class="graphic graphic_table graphicRef77498" href="/z/d/graphic/77498.html" rel="external">table 1</a>) and the range of expected changes in the lipid profile are listed in a separate table  (<a class="graphic graphic_table graphicRef75715" href="/z/d/graphic/75715.html" rel="external">table 2</a>).</p><p>Lipid lowering, at least with statins, is beneficial for primary and secondary prevention of coronary heart disease in patients with dyslipidemias. (See  <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">"Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"</a> and  <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a>.)</p><p>The mechanisms of benefit seen with lipid lowering are incompletely understood. Regression of atherosclerosis occurs in only a minority of patients; furthermore, clinical benefits of lipid lowering are seen in as little as six months, before significant regression could occur. Thus, other factors must contribute; these include plaque stabilization, reversal of endothelial dysfunction, and decreased thrombogenicity. (See  <a class="medical medical_review" href="/z/d/html/4546.html" rel="external">"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease"</a>.)</p><p>The characteristics and efficacy of the statins will be reviewed here  (<a class="graphic graphic_table graphicRef53730" href="/z/d/graphic/53730.html" rel="external">table 3</a>). The efficacy of fibrates, lipid-lowering drugs other than statins and fibrates, and diet and dietary supplements are also discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4562.html" rel="external">"Low-density lipoprotein cholesterol lowering with drugs other than statins and PCSK9 inhibitors"</a> and  <a class="medical medical_review" href="/z/d/html/4561.html" rel="external">"Lipid management with diet or dietary supplements"</a> and  <a class="medical medical_review" href="/z/d/html/4562.html" rel="external">"Low-density lipoprotein cholesterol lowering with drugs other than statins and PCSK9 inhibitors", section on 'Fibrates'</a>.)</p><p>The major adverse reaction limiting statin use is the development of muscle symptoms, a condition known as statin-associated muscle symptoms (SAMS). This problem, including predisposing drug interactions, is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6833.html" rel="external">"Statin muscle-related adverse events"</a>.)</p><p>Therapeutic decision-making in patients with elevated lipid levels, including indications for and dosing of statins, is also discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">"Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"</a> and  <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span>Available statins include <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">lovastatin</a>, <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">pravastatin</a>, <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a>, <a class="drug drug_general" data-topicid="8473" href="/z/d/drug information/8473.html" rel="external">fluvastatin</a>, <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a>, <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a>, and <a class="drug drug_general" data-topicid="9532" href="/z/d/drug information/9532.html" rel="external">pitavastatin</a>  (<a class="graphic graphic_table graphicRef53730" href="/z/d/graphic/53730.html" rel="external">table 3</a>). These agents are competitive inhibitors of hydroxymethylglutaryl (HMG) CoA reductase, the rate-limiting step in cholesterol biosynthesis  (<a class="graphic graphic_figure graphicRef57263" href="/z/d/graphic/57263.html" rel="external">figure 1</a>). They occupy a portion of the binding site of HMG CoA, blocking access of this substrate to the active site on the enzyme [<a href="#rid1">1</a>].</p><p>A reduction in intrahepatic cholesterol leads to an increase in low-density lipoprotein (LDL) receptor turnover that results from an enhanced rate of hepatic LDL receptor cycling [<a href="#rid2">2</a>]. Statins also reduce very low-density lipoprotein (VLDL) production via an effect mediated by hepatic apolipoprotein B secretion [<a href="#rid3">3,4</a>], which is associated with a diminished rate of recovery of HMG CoA reductase activity after drug treatment [<a href="#rid5">5</a>].</p><p>Most of the statins have modest high-density lipoprotein (HDL) cholesterol raising properties (approximately 5 percent), although <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a> has a larger effect (see <a class="local">'Effect on HDL'</a> below). Triglyceride concentrations fall by an average of 20 to 40 percent depending upon the statin and dose used (see <a class="local">'Effect on triglycerides'</a> below). The clinical relevance of these differences is uncertain. The reduction in plasma triglycerides is due to a decrease in VLDL synthesis and to clearance of VLDL remnant particles by apolipoprotein B/E (LDL) receptors.</p><p>The mechanisms by which statins may affect cardiovascular disease are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4546.html" rel="external">"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">EFFICACY</span><span class="headingEndMark"> — </span>The statins are commonly used in the treatment of hypercholesterolemia and mixed hyperlipidemia.</p><p class="headingAnchor" id="H4"><span class="h2">Effect on LDL cholesterol</span></p><p class="headingAnchor" id="H5"><span class="h3">Potency</span><span class="headingEndMark"> — </span>Aside from proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, statins are the most powerful drugs for lowering low-density lipoprotein (LDL) cholesterol, with reductions in the range of 30 to 63 percent  (<a class="graphic graphic_table graphicRef53730" href="/z/d/graphic/53730.html" rel="external">table 3</a>) [<a href="#rid6">6-10</a>]. When switching between statin drugs, equipotent doses with regard to LDL cholesterol reduction can be found in the figure  (<a class="graphic graphic_figure graphicRef60663" href="/z/d/graphic/60663.html" rel="external">figure 2</a>).</p><p><a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">Rosuvastatin</a> is somewhat more potent than <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> [<a href="#rid10">10,11</a>], and both these agents are significantly more potent than <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a>, <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">lovastatin</a>, <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">pravastatin</a>, and <a class="drug drug_general" data-topicid="8473" href="/z/d/drug information/8473.html" rel="external">fluvastatin</a> [<a href="#rid11">11,12</a>]. At maximal prescribed doses, LDL cholesterol reduction is greater with rosuvastatin and atorvastatin than with the other available statins  (<a class="graphic graphic_figure graphicRef60663" href="/z/d/graphic/60663.html" rel="external">figure 2</a>).</p><p>At doses of up to 40 mg/day, <a class="drug drug_general" data-topicid="8473" href="/z/d/drug information/8473.html" rel="external">fluvastatin</a> is the least potent statin  (<a class="graphic graphic_figure graphicRef60663" href="/z/d/graphic/60663.html" rel="external">figure 2</a>). However, at doses of 80 mg/day, fluvastatin is as effective on lowering LDL cholesterol as most statins other than <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a> and <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> [<a href="#rid13">13</a>]. Fluvastatin, <a class="drug drug_general" data-topicid="9532" href="/z/d/drug information/9532.html" rel="external">pitavastatin</a>, and <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">pravastatin</a> are less likely to have drug interactions or produce muscle toxicity than some other statins. (See <a class="local">'Side effects'</a> below.)</p><p>Although <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a> 80 mg/day is a high-intensity dose of statin, given high rates of adverse muscle symptoms including rhabdomyolysis [<a href="#rid14">14</a>] and the availability of generic <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a> and <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a>, we suggest not treating patients with doses of simvastatin above 40 mg/day. Additionally, clinicians should strongly consider switching even patients who are currently tolerating simvastatin 80 mg/day to one of these other statin options since future medication therapy or illness could increase the risk for development of myopathy on high-dose simvastatin. High-dose simvastatin may be appropriate for a small number of patients who have tolerated it well for many years or who are intolerant of other high-potency statin options.</p><p>There is an additive hypolipidemic effect when any of the statins is used in combination with a bile acid sequestrant  (<a class="graphic graphic_figure graphicRef63912" href="/z/d/graphic/63912.html" rel="external">figure 3</a>) [<a href="#rid15">15-17</a>], or the cholesterol absorption inhibitor <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">ezetimibe</a>. (See  <a class="medical medical_review" href="/z/d/html/4562.html" rel="external">"Low-density lipoprotein cholesterol lowering with drugs other than statins and PCSK9 inhibitors", section on 'Ezetimibe'</a>.)</p><p class="headingAnchor" id="H6"><span class="h3">LDL subfractions</span><span class="headingEndMark"> — </span>Statins are the most effective oral agents for lowering total LDL particle concentration; however, they are nonselective for reducing LDL subclasses; they reduce the predominant subclass [<a href="#rid18">18</a>]. Among patients with the atherogenic dyslipidemia profile, the reduction in the predominant subclass of small, dense LDL particles results in a shift of the LDL subfractions to more buoyant, and potentially less atherogenic, LDL [<a href="#rid19">19-21</a>]. (See  <a class="medical medical_review" href="/z/d/html/4567.html" rel="external">"Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia", section on 'Small dense LDL (LDL phenotype B)'</a> and  <a class="medical medical_review" href="/z/d/html/4565.html" rel="external">"Lipoprotein classification, metabolism, and role in atherosclerosis", section on 'Intermediate-density lipoprotein (remnant lipoproteins)'</a> and  <a class="medical medical_review" href="/z/d/html/4565.html" rel="external">"Lipoprotein classification, metabolism, and role in atherosclerosis", section on 'Low-density lipoprotein'</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Effect on HDL</span><span class="headingEndMark"> — </span>Statin therapy alters high-density lipoprotein (HDL) cholesterol levels, typically raising them, but these effects vary by statin and by dose of statin and do not correlate with the effects on LDL cholesterol levels. As examples, <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a> and <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a> appear to raise HDL cholesterol more as the dose is increased, while the increase in HDL cholesterol seen with <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> is attenuated at higher doses [<a href="#rid22">22</a>]. In some patients, HDL cholesterol may decline on statin therapy. The variable effects of statins on HDL cholesterol levels and HDL function may be due to their effects on hepatic microRNA33 (miR33); inhibitory mRNA 33 interferes with macrophage ABCA1-mediated efflux [<a href="#rid23">23-25</a>]. Whether the changes seen in HDL cholesterol with statin therapy are clinically important is uncertain. (See  <a class="medical medical_review" href="/z/d/html/4560.html" rel="external">"HDL cholesterol: Clinical aspects of abnormal values"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Effect on triglycerides</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">Atorvastatin</a> and <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a> are more effective at lowering triglycerides (14 to 33 percent) than other statins in patients with hypercholesterolemia [<a href="#rid11">11,26-28</a>]. The magnitude of triglyceride lowering with statins may be as high as 40 to 44 percent in patients with hypertriglyceridemia.</p><p>The effects of <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> and <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a> on serum triglycerides are dose-dependent [<a href="#rid11">11,26</a>]. As an example, in a series of 56 patients with primary hypertriglyceridemia in whom the average triglyceride concentration was 600 mg/dL and LDL cholesterol concentration was 120 mg/dL (3.1 mmol/L), the administration of atorvastatin at doses of 5, 20, or 80 mg/day produced reductions in triglycerides of 27, 32, and 46 percent, respectively, and in LDL cholesterol of 17, 33, and 41 percent, respectively [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Genetic/race effects</span><span class="headingEndMark"> — </span>Part of the variability in the response to and side effects with statins may be related to genetic differences in the rate of drug metabolism. As an example, CYP2D6 is a member of the cytochrome P450 superfamily of drug oxidizing enzymes. CYP2D6 is functionally absent in 7 percent of White and African American individuals, while deficiency is rare among Asian persons.</p><p>The CYP2D6 phenotype appears to be important in patients treated with <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a>, as it can affect both the degree of lipid lowering and tolerability [<a href="#rid29">29</a>]. Polymorphisms in the gene coding for hydroxymethylglutaryl (HMG) CoA reductase also appear to affect the LDL cholesterol response to statins, but not the HDL cholesterol response [<a href="#rid30">30</a>].</p><p>Concerns have been raised that persons from Asia (mostly China, Japan and Korea) may have greater responses to low doses of statins than European American individuals [<a href="#rid31">31</a>]. Prescribing information for <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a> recommends starting therapy at a lower initial dose in Asian individuals than in other groups, given observed differences in pharmacokinetics [<a href="#rid32">32</a>]. There is no strong evidence supporting such an approach with other statins.</p><p class="headingAnchor" id="H10"><span class="h2">Prevention of cardiovascular disease</span><span class="headingEndMark"> — </span>The major use of statins is in the primary and secondary prevention of cardiovascular disease. This use is discussed extensively elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">"Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/100.html" rel="external">"Low-density lipoprotein-cholesterol (LDL-C) lowering after an acute coronary syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4546.html" rel="external">"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease"</a>.)</p><p></p><p class="headingAnchor" id="H3085936214"><span class="h2">Noncardiovascular disease outcomes</span><span class="headingEndMark"> — </span>A pooled analysis of meta-analyses of observational studies and randomized trials examining outcomes of statin found no convincing evidence of an association between statins and most noncardiovascular disease outcomes [<a href="#rid33">33</a>]. A possible exception may be a beneficial effect on all-cause mortality among patients with renal disease. (See <a class="local">'Renal dysfunction'</a> below.)</p><p class="headingAnchor" id="H11"><span class="h1">SIDE EFFECTS</span></p><p class="headingAnchor" id="H2882353898"><span class="h2">Frequency</span><span class="headingEndMark"> — </span>Adverse reactions occur less frequently with the statins than with most other classes of lipid-lowering agents. Adverse muscle events remain important side effects [<a href="#rid34">34,35</a>] (see  <a class="medical medical_review" href="/z/d/html/6833.html" rel="external">"Statin muscle-related adverse events"</a>). Hepatic dysfunction has been a source of concern; however, the actual risk appears to be very small.</p><p>In randomized trials, statin therapy appears to cause only a slight increased risk of side effects compared with placebo, and no increased risk of discontinuation of therapy compared with placebo [<a href="#rid36">36,37</a>]. In a 2017 meta-analysis of 22 placebo-controlled trials on statin use involving nearly 130,000 participants, 13.3 percent of subjects receiving a statin discontinued the drug compared with 13.9 percent of subjects on placebo (odds ratio [OR] 0.99, 95% CI 0.93-1.06) over a mean follow-up of 4.1 years [<a href="#rid38">38</a>]. In clinical practice, side effects with statins are common, which could be related in part to a heightened awareness of adverse reactions traditionally attributed to the drug and treatment in patients with comorbidities that were often excluded from clinical trials. In a randomized double-blind, placebo-controlled trial involving over 10,000 patients, <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> therapy was not associated with an increased rate of muscle-related adverse events [<a href="#rid39">39</a>]. By contrast, in a subsequent nonrandomized, nonblinded extension of the study, muscle-related adverse events were reported more often in patients taking atorvastatin compared with placebo (1.26 versus 1.00 percent per annum). These results suggest that some muscle-related adverse events attributed to atorvastatin are not causally linked to the drug.</p><p>There have been concerns that the more lipophilic statins (<a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a>, <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">lovastatin</a>, <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a>, and <a class="drug drug_general" data-topicid="8473" href="/z/d/drug information/8473.html" rel="external">fluvastatin</a>) may be associated with more adverse events than the more hydrophilic statins (<a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">pravastatin</a> and <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a>) [<a href="#rid40">40,41</a>]; however, fluvastatin (a lipophilic statin) appears to have a low rate of muscle side effects [<a href="#rid42">42</a>]. Differences in adverse events may derive from heterogeneity in drug elimination pathways [<a href="#rid34">34,35</a>].</p><p class="headingAnchor" id="H2941868602"><span class="h2">Management considerations</span><span class="headingEndMark"> — </span>As discussed above, while data from clinical trials suggest low rates of statin side effects leading to discontinuation, in clinical experience, it is relatively common to find patients who are intolerant of one or more statins because of myalgias or other muscular symptoms. Less commonly, aminotransferase elevations require making changes in the statin, the statin dosage, or changes to another class of cholesterol-lowering therapy.</p><p>The approach to managing <strong>statin-induced muscle adverse events</strong> is shown in the algorithm and is discussed in detail separately  (<a class="graphic graphic_algorithm graphicRef97520" href="/z/d/graphic/97520.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/6833.html" rel="external">"Statin muscle-related adverse events", section on 'Management'</a>.)</p><p>Options in patients with <strong>aminotransferase elevations</strong> (more than three times the upper limit of normal; confirmed on repeat testing) are similar, and include (see <a class="local">'Hepatic dysfunction'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>Use of a different statin</p><p class="bulletIndent1"><span class="glyph">●</span>Dose reduction</p><p class="bulletIndent1"><span class="glyph">●</span>Alternate day therapy (see <a class="local">'Alternative dosing regimens'</a> below)</p><p></p><p>Observational data suggest that, while discontinuation of statin therapy for side effects is relatively common, many patients tolerate the same drug or another statin when rechallenged [<a href="#rid43">43,44</a>]. In addition, there may be risk associated with discontinuing statin therapy. In a retrospective cohort study of 28,266 patients on statins who reported an adverse reaction, over 70 percent were able to remain on therapy [<a href="#rid44">44</a>]. Of note, four years later, the cumulative incidence of a cardiovascular event (myocardial infarction or stroke) or death was lower in patients who continued on statin therapy compared with those who had stopped it (12.2 versus 13.9 percent [hazard ratio [HR] 0.87, 95% CI 0.81-0.93]). In another study of 105,329 Medicare beneficiaries following hospitalization for myocardial infarction, statin down-titration or discontinuation compared with adherence to high-intensity statin therapy over a median of 1.9 to 2.3 years of follow-up was associated with an increased risk of recurrent myocardial infarction (HR 1.50, 95% CI 1.30-1.73) [<a href="#rid45">45</a>].</p><p>Some patients do not tolerate statin therapy even after changing to a different statin, reducing the dose, and/or using alternate-day dosing. The clinical management of patients unable to take statin therapy for secondary prevention is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/100.html" rel="external">"Low-density lipoprotein-cholesterol (LDL-C) lowering after an acute coronary syndrome", section on 'Statin intolerance'</a> and  <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Hepatic dysfunction</span><span class="headingEndMark"> — </span>Clinical studies of statins have demonstrated a 0.5 to 3.0 percent occurrence of persistent elevations in aminotransferases in patients receiving statins. This has primarily occurred during the first three months of therapy and is dose-dependent.</p><p>Rare episodes of more severe liver injury have also been seen, and one study suggested that these predominantly occur three to four months after initiation of statin therapy [<a href="#rid46">46</a>], with a range in one study of one month to 10 years [<a href="#rid47">47</a>]. However, these are sufficiently uncommon that the overall incidence of hepatic failure in patients taking statins appears to be no different from the incidence in the general population [<a href="#rid48">48</a>]. The pattern of more severe hepatotoxicity attributed to statins has included hepatocellular, cholestatic, and autoimmune injury [<a href="#rid47">47</a>].</p><p>Several randomized trials have reported no significant difference in the incidence of persistently elevated aminotransferases between statin and placebo therapy [<a href="#rid49">49-51</a>]. A similar finding was noted in a review of three <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">pravastatin</a> trials with over 112,000 patient-years of exposure [<a href="#rid52">52</a>]. There was no difference in the incidence or severity of serum aminotransferase elevations with pravastatin or placebo, including patients with aminotransferase elevations at study entry. A meta-analysis of 35 randomized trials found an excess risk of aminotransferase elevation with statin therapy versus placebo of 4.2 cases per 1000 patients [<a href="#rid36">36</a>].</p><p>A large cohort study from England and Wales found similar risks of hepatic dysfunction with different statins, with the exception of a higher risk with <a class="drug drug_general" data-topicid="8473" href="/z/d/drug information/8473.html" rel="external">fluvastatin</a> [<a href="#rid53">53</a>].</p><p>A review of one year of records for 1014 patients taking statins in a primary care practice found that 1 percent of patients had transaminase elevations more than three times normal and 0.5 percent had transaminase elevations two to three times normal [<a href="#rid54">54</a>]. None of these elevations appeared to be related to statin use. Similarly, a review of five years of a health maintenance organization's computerized records on 23,000 patients who were receiving statins found that 17 (0.1 percent) had an alanine aminotransferase (ALT) level more than 10 times the upper limit of normal that appeared to be attributable to statin therapy [<a href="#rid55">55</a>]. Of these, all but four were associated with drug interactions.</p><p>In 2012, the US Food and Drug Administration (FDA) revised its labeling information on statins to only recommend liver function testing prior to initiation of statin therapy and to only repeat such testing for clinical indications [<a href="#rid56">56</a>]. We and others agree that routine monitoring of liver function tests in patients receiving statin therapy is not necessary [<a href="#rid51">51,55,57,58</a>].</p><p>We recommend changing medications or lowering the statin dose in patients who are found to have an ALT level more than three times the upper limit of normal that is confirmed on a second occasion.</p><p class="headingAnchor" id="H13"><span class="h2">Muscle injury</span><span class="headingEndMark"> — </span>Development of muscle toxicity is a concern with the use of statins. This problem, including predisposing drug interactions and an approach to management, is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6833.html" rel="external">"Statin muscle-related adverse events"</a>.)</p><p>Hypothyroidism is a potential cause of dyslipidemia (see  <a class="medical medical_review" href="/z/d/html/7857.html" rel="external">"Lipid abnormalities in thyroid disease"</a>), and hypothyroidism may predispose patients to statin-induced myopathy [<a href="#rid59">59,60</a>] (see  <a class="medical medical_review" href="/z/d/html/6833.html" rel="external">"Statin muscle-related adverse events", section on 'Hypothyroidism, hypovitaminosis D, and other disorders'</a>). As such, we suggest checking a thyroid-stimulating hormone level prior to initiating statin therapy.</p><p class="headingAnchor" id="H14"><span class="h2">Renal dysfunction</span><span class="headingEndMark"> — </span>Statins appear to be able to cause proteinuria through tubular inhibition of active transport of small molecular weight proteins [<a href="#rid61">61,62</a>]. There have been a number of reports to the FDA about proteinuria with statins, particularly in patients receiving <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a> or <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a> [<a href="#rid63">63</a>]. However, it is believed that proteinuria with statins is a benign finding [<a href="#rid64">64,65</a>].</p><p>There have also been rare episodes of renal failure in clinical trials of patients treated with 80 mg/day of <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a> [<a href="#rid11">11</a>], a higher dose than is available. However, it is unclear if rosuvastatin was responsible for the renal failure, as these patients were on other potentially nephrotoxic medications. Although concerns had been raised about high rates of adverse event reports to the FDA regarding rosuvastatin [<a href="#rid63">63</a>], subsequent information suggested that renal adverse events with rosuvastatin are rare and are similar to those seen with other statins [<a href="#rid66">66-69</a>]. However, in a cohort study comparing adverse renal events over an eight-year period among 152,101 new users of rosuvastatin with 795,799 new users of <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a>, treatment with rosuvastatin was associated with increased risk of hematuria (HR 1.08, 95% CI 1.04-1.11), proteinuria (HR 1.17, 95% CI 1.10-1.25), and kidney failure with replacement therapy (HR 1.15, 95% CI 1.02-1.30) [<a href="#rid70">70</a>]. These findings may be partially due to the fact that among those patients with estimated glomerular filtration rate (eGFR) &lt;30 mL/min per 1.73 m<sup>2</sup>, 44 percent were prescribed a rosuvastatin daily dose that exceeded the recommended 10 mg daily dose.</p><p>A large database study found an association between high potency statins and hospital admission for acute kidney injury, particularly in the first 120 days after initiation of statin therapy [<a href="#rid71">71</a>]. One pooled analysis of randomized trials did not find evidence of an increase in acute kidney injury [<a href="#rid72">72</a>], whereas another did show an adverse effect [<a href="#rid33">33</a>].</p><p>A pooled analysis of meta-analyses of randomized trials examining outcomes of statin use demonstrated reduced all-cause mortality in patients with chronic kidney disease, which may have been due to a reduction in cardiovascular disease events [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H15"><span class="h2">Behavioral and cognitive</span><span class="headingEndMark"> — </span>Although concerns have been raised about increased suicide in patients treated with some lipid-lowering therapies, statins do not appear to be associated with an increased risk of suicide or depression [<a href="#rid73">73</a>]. (See  <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a>.)</p><p>There have been case reports of patients developing severe irritability and aggression associated with the use of statins [<a href="#rid74">74</a>]. It is not known whether the statin use caused these symptoms, but very rare idiosyncratic reactions of this sort could be missed in controlled trials.</p><p>A retrospective cohort study in older adult patients found an association between perioperative statin use and postoperative delirium [<a href="#rid75">75</a>]; however, it is difficult to tell whether this association was causal [<a href="#rid76">76</a>]. Perioperative administration of statins may have important cardiovascular benefits. (See  <a class="medical medical_review" href="/z/d/html/4814.html" rel="external">"Perioperative medication management", section on 'Statins'</a>.)</p><p>Concerns have been raised in the media and popular press about cognitive dysfunction and memory loss associated with statin use [<a href="#rid77">77,78</a>]. A review of adverse events reported to the FDA between November 1997 and February 2002 found 60 reports of patients who had memory loss associated with statins [<a href="#rid79">79</a>]. Fourteen of 25 patients had improvement when the statin was discontinued, and four had recurrence of memory loss on rechallenge. The statins involved were <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a> (36 patients), <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> (23 patients), and <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">pravastatin</a> (1 patient).</p><p>Although this analysis of adverse event reports does not show that statins cause memory loss, the apparently high rate of reports with lipophilic statins (<a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a> and <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a>) compared with hydrophilic statins (<a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">pravastatin</a>) does suggest a possible biologic effect. Randomized trials of <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">lovastatin</a> and simvastatin have shown some evidence of minor decrements in cognitive function as measured by neuropsychological testing [<a href="#rid80">80,81</a>]. A systematic review of randomized trials and observational studies found that published data do not suggest that statins harm cognition; however, the quality of the evidence was felt to be only low to moderate, particularly with regard to high-intensity statin therapy [<a href="#rid82">82</a>]. A 2015 systematic review of randomized trials similarly concluded that statin therapy was not associated with harming cognitive function in either cognitively normal patients or those with Alzheimer disease [<a href="#rid83">83</a>]. However, randomized trials can fail to detect rare medication side effects. A large database observational study found an association between first exposure to statin therapy and acute memory loss (within 30 days); however, the same association was found for other lipid-lowering agents and the authors thought it more likely that the result reflected detection bias rather than a true causal effect of multiple lipid-lowering therapies [<a href="#rid84">84</a>]. In our experience, we have encountered rare patients who appear to experience cognitive side effects on a statin that resolve with discontinuation and recur with reinstitution; some of these patients appear to tolerate an alternative statin.</p><p>In the absence of more definitive data, it may be appropriate for clinicians to determine whether statin therapy was recently initiated in patients who develop new memory loss. If an individual patient appears to have memory loss associated with lipophilic statin therapy (<a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a>, <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">lovastatin</a>, <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a>, or <a class="drug drug_general" data-topicid="8473" href="/z/d/drug information/8473.html" rel="external">fluvastatin</a>) and has a strong indication for lipid-lowering therapy, it would be reasonable to attempt treatment with a more hydrophilic statin (<a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">pravastatin</a> or <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a>) [<a href="#rid85">85</a>].</p><p>In contrast to the above observations suggesting that statins may produce cognitive impairment, other studies have suggested that statins may have a role in the prevention of dementia. (See  <a class="medical medical_review" href="/z/d/html/5075.html" rel="external">"Prevention of dementia", section on 'Statins'</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Diabetes mellitus</span><span class="headingEndMark"> — </span>It appears likely that statin therapy confers a small increased risk of developing diabetes and that the risk is slightly greater with intensive statin therapy than moderate statin therapy. As would be expected, given the evidence from clinical trials that statins reduce cardiovascular events in patient with diabetes (see  <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a>), both randomized trials and observational studies suggest that the beneficial effects of statins on cardiovascular events and mortality outweigh any increased risk conferred by promoting the development of diabetes [<a href="#rid86">86,87</a>].</p><p>Statins could have effects on glucose metabolism that might influence the development of diabetes mellitus in nondiabetics or affect glycemic control in patients with existing diabetes. Experimental evidence has been conflicting about whether statins as a group improve glucose metabolism or whether some statins show beneficial effects while others show harmful effects [<a href="#rid88">88-93</a>].</p><p>Some clinical trials of statins had reported conflicting results on the issue of glucose metabolism [<a href="#rid94">94-97</a>]. However, a 2010 meta-analysis of 13 trials (n = 91,140) found little evidence of heterogeneity among large-scale chronic treatment trials [<a href="#rid98">98</a>]. For inclusion, trials were required to have more than 1000 patients and a duration of follow-up of more than one year. This meta-analysis found an overall small increased risk for diabetes in patients treated with statins (OR for incident diabetes 1.09, 95% CI 1.02-1.17). Subgroup analyses found very similar diabetes risks in trials of hydrophilic or lipophilic statins, and no clear differences among individual statins. The results were also similar after the exclusion of the JUPITER trial. Since JUPITER had raised much of the concern about diabetes and statins [<a href="#rid95">95</a>], the stability of the result without JUPITER lowers the likelihood that the glucose findings in the meta-analysis were due to chance.</p><p>A 2011 meta-analysis of five randomized trials (n = 32,752) also found an increased risk of incident diabetes with intensive statin therapy compared with moderate statin therapy (OR 1.12, CI 1.04-1.22) with little or no heterogeneity across trials [<a href="#rid99">99</a>]. This translates into approximately one additional case of diabetes for every 500 patients treated with intensive rather than moderate statin therapy. Similarly, a large observational study using administrative data found a higher risk of diabetes with high-potency statins, an intermediate risk with moderate-potency statins, and a lower risk with low-potency statins [<a href="#rid100">100</a>].</p><p>A 2015 meta-analysis confirmed these results both for the risk of diabetes with statins versus placebo (OR 1.11, CI 1.03-1.20) and for intensive versus moderate-intensity statin therapy (OR 1.12, 1.04-1.22) [<a href="#rid101">101</a>]. This study also included a Mendelian randomization study (see  <a class="medical medical_review" href="/z/d/html/13514.html" rel="external">"Mendelian randomization"</a>) that found that decreased genetic hydroxymethylglutaryl (HMG) CoA reductase activity is associated with a higher risk of type 2 diabetes, such that at least some of the risk seen with statin therapy appears to be due to its on-target effect of inhibiting HMG CoA reductase. This is important because it means that this side effect of statins cannot likely be eliminated while maintaining the primary efficacy of statin therapy [<a href="#rid102">102</a>].</p><p>A 2016 analysis estimated that high-dose statin therapy (eg, <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> 40 mg/day) would lead to 50 to 100 new cases of diabetes in 10,000 treated individuals [<a href="#rid103">103</a>].</p><p class="headingAnchor" id="H18"><span class="h2">Other possible associations</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cancer</strong> – There is no convincing evidence from meta-analyses of randomized trial that statins increase or decrease the risk of cancer [<a href="#rid33">33,104-110</a>].</p><p></p><p class="bulletIndent1">Statin eligibility for primary prevention using American College of Cardiology/American Heart Association (ACC/AHA) criteria may predict cancer risk and mortality. In a Framingham Heart Study analysis, the incident cancer rate was 15 percent in the statin-eligible group compared with 8.8 percent in those who were ineligible (HR 1.8, 95% CI 1.4-2.3) [<a href="#rid111">111</a>]. Cancer-related deaths occurred in 4.2 percent of the statin-eligible group compared with 0.4 percent in those who were ineligible (HR 12.1, 95% CI 4.7-31). In a stratified analysis, these findings were independent of known cancer risk factors such as increased body mass index, increased age, and smoking history. While the explanation for this observation is unclear, these results suggest that factors contributing to statin eligibility may also be predictive of an increased risk of cancer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cataract</strong> – Most large case-control and cohort studies [<a href="#rid112">112-114</a>], as well as a small randomized trial [<a href="#rid115">115</a>], have not found an increased risk of cataract, although large cohort studies from England, Wales, and the United States military health system have found that statin use was associated with an increased risk of cataract [<a href="#rid53">53,116</a>].</p><p></p><p class="bulletIndent1">In a subset analysis, one cohort study reported an association between statins and a decreased risk of one type of cataract (nuclear cataract) [<a href="#rid114">114</a>]. An analysis of safety results from a randomized trial also found an apparent protective effect of lipid-lowering therapy with <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a> plus <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">ezetimibe</a> [<a href="#rid117">117</a>]; however, there were very few cataract events, the types of cataracts were not reported, the result was of borderline statistical significance, and reporting bias is a concern with these sorts of results from safety data. Additional study is clearly needed before it can be concluded that statins actually have any such protective effect.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuropathy</strong> – A number of studies have suggested that statin use may be associated with the development of peripheral neuropathy. However, a 2020 systematic review of 13 studies concluded that there was insufficient evidence that statin use was a risk factor for polyneuropathy, and that the available studies had methodological flaws [<a href="#rid118">118</a>]. A small case-control study, conducted by the same authors, did not find an association between patients with polyneuropathy and prior statin use [<a href="#rid118">118</a>]. As such, a causal association between statin use and neuropathy remains possible but has not been proven.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lupus</strong> – There have been case reports of drug-induced lupus in patients receiving statins. (See  <a class="medical medical_review" href="/z/d/html/4677.html" rel="external">"Drug-induced lupus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Androgen synthesis</strong> – Some [<a href="#rid119">119,120</a>], but not all [<a href="#rid121">121</a>], studies suggest that statins may lower androgen levels in men, although it appears unlikely that this effect is clinically significant [<a href="#rid122">122</a>]. Statins may also reduce androgen levels in women, including in women with androgen excess [<a href="#rid93">93</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune response</strong> – Some observational studies have suggested that the immune response to influenza immunization, and the efficacy of that immunization in preventing clinical influenza, may be reduced in older adults patients receiving statin therapy. The possible implications of these results for patient management are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">"Seasonal influenza vaccination in adults"</a>.)</p><p></p><p class="headingAnchor" id="H19"><span class="h2">Risks in pregnancy and breastfeeding</span><span class="headingEndMark"> — </span>In the United States, the FDA has recommended that statins be discontinued in most pregnant patients [<a href="#rid123">123</a>]. However, clinicians may consider their use in patients at very high risk of cardiovascular events during pregnancy, such as those with homozygous familial hypercholesterolemia or established cardiovascular disease. Breastfeeding is still not recommended in patients taking a statin, and clinicians are advised to determine whether it is better to temporarily stop statin therapy while breastfeeding or to continue statin therapy and not have the patient breastfeed. We strongly advise a patient-clinician dialogue to discuss the risks and benefits of continued statin therapy versus alternative treatments (eg, apheresis) to lower low-density lipoprotein (LDL) cholesterol during pregnancy and breastfeeding. Documentation of these discussions should be entered into the medical record.</p><p>If a statin is to be discontinued during pregnancy, we recommend, based on the drug half-life, withdrawal a minimum of 6 weeks and preferably 12 weeks before planned conception.</p><p class="headingAnchor" id="H20"><span class="h1">ADMINISTRATION</span></p><p class="headingAnchor" id="H21"><span class="h2">Timing of administration</span><span class="headingEndMark"> — </span>The majority of cholesterol synthesis appears to occur at night [<a href="#rid124">124</a>], presumably reflecting the effects of a fasting state. For this reason, it is typically recommended that the statins with shorter half-lives be administered in the evening or at bedtime  (<a class="graphic graphic_table graphicRef53730" href="/z/d/graphic/53730.html" rel="external">table 3</a>).</p><p>In support of this, trials have found greater reductions in total and low-density lipoprotein (LDL) cholesterol when <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a>, which has a relatively short half-life, is administered in the evening rather than in the morning [<a href="#rid125">125,126</a>]. A small study of <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a>, which has a long half-life, found no significant differences whether it was administered in the morning or the evening [<a href="#rid127">127</a>].</p><p>While it is unknown whether the timing of statin administration is important for clinical outcomes, we typically administer statins at the time recommended by the manufacturer  (<a class="graphic graphic_table graphicRef53730" href="/z/d/graphic/53730.html" rel="external">table 3</a>). <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">Lovastatin</a> absorption is increased by food, and it should be administered with the morning and evening meals.</p><p class="headingAnchor" id="H22"><span class="h2">Alternative dosing regimens</span><span class="headingEndMark"> — </span>Every-other-day statin therapy has been suggested as a strategy to improve utilization and decrease cost. Small studies have compared daily statin use with alternate-day dosing, and measured effects on lipid parameters and, in some cases, attainment of cholesterol goals over 6 to 12 weeks [<a href="#rid128">128-132</a>]. Every-other-day regimens, and even once-weekly regimens, have also been evaluated as strategies for improving tolerability [<a href="#rid133">133-135</a>].</p><p>Results with <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a>, <a class="drug drug_general" data-topicid="8473" href="/z/d/drug information/8473.html" rel="external">fluvastatin</a>, and <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a> suggest that to yield similar LDL cholesterol lowering, the every-other-day dose needs to be on average nearly twice that of the daily dose [<a href="#rid128">128,129,131,135</a>]. There are few data on alternate-day regimens using a dose greater than 40 mg or on how patient adherence is impacted.</p><p>Major outcomes trials of statins have used daily statin therapy. In the absence of data from large randomized trials demonstrating equivalent effects on clinical outcomes with alternative dosing regimens, we suggest daily dosing in patients who are treated with statins. We prefer other measures for cost control, such as price comparison among generic statins [<a href="#rid136">136</a>]. Clinical experience suggests that alternate-day dosing may improve the tolerability of statins in patients experiencing myalgias, and this strategy can reasonably be tried in patients unable to tolerate daily statin therapy. (See  <a class="medical medical_review" href="/z/d/html/6833.html" rel="external">"Statin muscle-related adverse events", section on 'Alternate-day dosing'</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Interchange</span><span class="headingEndMark"> — </span>When switching between statin drugs, equipotent doses with regard to LDL cholesterol reduction can be found in the figure  (<a class="graphic graphic_figure graphicRef60663" href="/z/d/graphic/60663.html" rel="external">figure 2</a>). (See <a class="local">'Potency'</a> above.)</p><p><a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">Simvastatin</a> and <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> may be associated with more adverse events than <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">pravastatin</a> or <a class="drug drug_general" data-topicid="8473" href="/z/d/drug information/8473.html" rel="external">fluvastatin</a> [<a href="#rid42">42</a>]. (See <a class="local">'Side effects'</a> above.)</p><p class="headingAnchor" id="H24"><span class="h2">Drug interactions</span><span class="headingEndMark"> — </span>The uptake, metabolism, and clearance of each statin differs, and therefore each statin is subject to different types of drug interactions  (<a class="graphic graphic_table graphicRef53730" href="/z/d/graphic/53730.html" rel="external">table 3</a>). <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">Simvastatin</a>, <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">lovastatin</a>, and to a lesser extent <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> are metabolized by cytochrome P450 3A4 (CYP3A4). <a class="drug drug_general" data-topicid="8473" href="/z/d/drug information/8473.html" rel="external">Fluvastatin</a> clearance is partly dependent upon CYP2C9 metabolism, whereas <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a>, <a class="drug drug_general" data-topicid="9532" href="/z/d/drug information/9532.html" rel="external">pitavastatin</a>, and <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">pravastatin</a> are cleared primarily by non-CYP450 transformations [<a href="#rid137">137,138</a>].</p><p>The most common concern regarding a potential harmful drug interaction between a statin and another drug is induced muscle injury potentially leading to acute kidney injury. This risk is substantially greater in patients receiving concurrent therapy with a number of drugs, particularly those that inhibit statin metabolism (eg, by CYP3A4)  (<a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">table 4</a>) or transmembrane transporters (eg, organic anion transporting polypeptides [OATPs] or breast cancer resistance proteins [BCRP]) [<a href="#rid137">137</a>]. Additionally, concurrent use of a drug or drug class that is independently considered a risk factor for myopathy (ie, glucocorticoids, fibrates <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a>, <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">zidovudine</a>) may further increase risk of statin-related myopathy. This issue is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/6833.html" rel="external">"Statin muscle-related adverse events"</a>.)</p><p>Certain drug interactions are discussed below. Additional detail about specific statin interactions and management suggestions is available from the <a class="external" href="/drug-interactions">drug interactions program</a> included within UpToDate.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CYP3A4 drugs</strong> – Drugs and substances that inhibit CYP3A4  (<a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">table 4</a>) can increase the risk of statin myopathy when administered with statins extensively metabolized by CYP3A4 (eg, <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">lovastatin</a>, <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a>, and to a lesser extent <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a>)  (<a class="graphic graphic_table graphicRef53730" href="/z/d/graphic/53730.html" rel="external">table 3</a>) [<a href="#rid138">138</a>]. Select examples are discussed below; however, this list is not exhaustive.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcium channel blockers</strong> – The non-dihydropyridine calcium channel blockers <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a> and <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a> are moderate inhibitors of CYP3A4 metabolism and can increase exposure to statins that are extensively metabolized by CYP3A4. Manufacturer data indicate that, at a <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a> dose of 20 to 80 mg/day, there is a 0.6 percent incidence of myopathy in patients also treated with verapamil (a value 10 times higher than seen in patients taking simvastatin without a calcium channel blocker) [<a href="#rid139">139</a>]. The risk is also increased when simvastatin is taken with the dihydropyridine calcium channel blocker, <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">amlodipine</a>, which is metabolized by and also weakly inhibits CYP3A4 [<a href="#rid140">140</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Human immunodeficiency virus (HIV) protease inhibitors</strong> – HIV protease inhibitors and pharmacologic boosters (eg, <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">ritonavir</a>, <a class="drug drug_general" data-topicid="97309" href="/z/d/drug information/97309.html" rel="external">cobicistat</a>) are potent inhibitors of CYP3A4. Thus, statins that are highly dependent upon CYP3A4 for clearance (eg, <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a>, <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">lovastatin</a>) are contraindicated for use by patients receiving HIV protease inhibitors and boosting agents [<a href="#rid140">140-142</a>]. In general, other statins may be used with HIV protease inhibitors and boosting agents, but interactions should be checked before initiating statin therapy by using a <a class="external" href="/drug-interactions">drug interactions program</a> as dose limitations may be required for some statins (eg, <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a>, <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a>) and complete avoidance for other statins (eg, simvastatin, lovastatin). A detailed discussion of statin therapy in patients with HIV is available elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3739.html" rel="external">"Management of cardiovascular risk (including dyslipidemia) in patients with HIV", section on 'Statin use'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">Amiodarone</a> – Amiodarone and its metabolites weakly inhibit CYP3A4 metabolism [<a href="#rid137">137</a>]. A pharmacokinetic study found a significant increase in <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a> exposure with amiodarone, and pharmacovigilance data suggest that there is an increased risk of myopathy and rhabdomyolysis, particularly with simvastatin doses greater than 20 mg/day [<a href="#rid140">140,143-146</a>]. The risk of rhabdomyolysis in patients treated concurrently with amiodarone appears to be higher with simvastatin than with other statins [<a href="#rid137">137</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Grapefruit juice</strong> – Grapefruit juice inhibits intestinal CYP3A4; however, daily consumption of 8 oz (240 mL) or less of grapefruit juice, or one-half of a grapefruit or less, is unlikely to increase the risk of an adverse interaction or muscle injury with most statins [<a href="#rid147">147</a>]. However, in a crossover study with <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a>, daily grapefruit juice consumption (200 mL) increased simvastatin exposure to 3.6 times the baseline [<a href="#rid148">148</a>]. For patients who consume large amounts of grapefruit or grapefruit juice, we recommend a hydrophilic statin (eg, <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a>, <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">pravastatin</a>, <a class="drug drug_general" data-topicid="9532" href="/z/d/drug information/9532.html" rel="external">pitavastatin</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>OATP inhibitors</strong> – OATPs are transport proteins that facilitate hepatic uptake of many drugs, including statins (properties of statins table). Though the role of OATPs in drug metabolism is not yet fully understood, OATP-mediated transport of statins from the systemic circulation into hepatocytes appears to be an important step preceding oxidative metabolism (eg, by CYP3A4) and/or biliary excretion (eg, by BCRP) [<a href="#rid149">149</a>]. OATP inhibition may increase statin serum concentrations and thereby increase adverse events including myopathy [<a href="#rid137">137</a>]. This may be additive with other pharmacokinetic effects such as CYP3A4 inhibition (as with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a>) or BCRP inhibition (as with some hepatitis C virus [HCV] protease inhibitor combinations). Manufacturer's labeling for certain statins (eg, <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a>, <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a>, <a class="drug drug_general" data-topicid="9532" href="/z/d/drug information/9532.html" rel="external">pitavastatin</a>) include specific dose limits for interactions with OATP inhibitors [<a href="#rid150">150-152</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> – Cyclosporine is an inhibitor and substrate of CYP3A4 and an inhibitor of CYP2C9, various OATPs (eg, OATP1B1, OATP1B3), and BCRP [<a href="#rid137">137,149</a>]. Cyclosporine coadministration can increase serum concentrations of all statins via complex pharmacokinetic interactions, thus contributing to increased risk for adverse effects [<a href="#rid137">137</a>]. For example, regular-dose <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">lovastatin</a> (40 to 80 mg/day) and <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a> (20 mg/day) are associated with an appreciable risk of myositis (as high as 13 to 30 percent) in cyclosporine-treated patients [<a href="#rid153">153-155</a>]. This is thought to be the result of cyclosporine inhibition of OATP1B1-mediated hepatic uptake of simvastatin and lovastatin and inhibition of CYP3A4 metabolism.</p><p></p><p class="bulletIndent1">Although <a class="drug drug_general" data-topicid="9532" href="/z/d/drug information/9532.html" rel="external">pitavastatin</a>, <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">pravastatin</a>, and <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a> are not significantly metabolized by CYP3A4, they interact with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> by non-CYP mechanisms (eg, by OATP1B1 and BCRP inhibition) [<a href="#rid150">150,152,156</a>]. Recommendations for statin therapy in patients with kidney and heart transplants is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/7303.html" rel="external">"Lipid abnormalities after kidney transplantation", section on 'Patients without established ASCVD (primary prevention)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HCV direct-acting antivirals (DAAs)</strong> – Many HCV DAAs increase statin exposure and toxicity. Though the mechanisms are not well-established, inhibition of transporters such as OATPs and BCRP appear to play an important role in statin interactions with DAAs (eg, <a class="drug drug_general" data-topicid="91660" href="/z/d/drug information/91660.html" rel="external">simeprevir</a>, sofosbuvir-velpatasivr, <a class="drug drug_general" data-topicid="114296" href="/z/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a>) [<a href="#rid150">150,157</a>]. CYP interactions may also occur, though this seems less common [<a href="#rid158">158</a>]. Interactions should be checked using a <a class="external" href="/drug-interactions">drug interactions program</a> before coadministration of statins with DAA-containing regimens.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fibrates</strong> – Fibrates are independently associated with muscle toxicity, and their concomitant use with statins can increase the risk of muscle injury, including rhabdomyolysis [<a href="#rid159">159</a>]. The effect is due in part to an increase in statin levels and varies according to the fibrate and statin. Toxicity can be minimized by the choice of fibrate and by using statins at relatively low doses [<a href="#rid160">160-162</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="91482" href="/z/d/drug information/91482.html" rel="external">Fenofibrate</a> is the preferred fibrate in patients who require combined therapy with a statin due to minimal risk of increase in statin levels [<a href="#rid40">40</a>]. It appears to be safer than <a class="drug drug_general" data-topicid="8488" href="/z/d/drug information/8488.html" rel="external">gemfibrozil</a> due to a differential effect on statin excretion [<a href="#rid163">163,164</a>]. The relative safety of fenofibrate has been demonstrated in meta-analyses and individual trials, in which there has been no increase in muscle-related adverse events in patients taking fenofibrate plus a statin compared with a statin alone [<a href="#rid165">165-167</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8488" href="/z/d/drug information/8488.html" rel="external">Gemfibrozil</a> has a greater potential to increase plasma levels of statins, especially when used with <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">lovastatin</a>, <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a>, or <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> [<a href="#rid153">153,168-170</a>]. This is in part related to potent inhibition of OATP1B1 by gemfibrozil, which is responsible for hepatic uptake of all statins. <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">Pravastatin</a> and <a class="drug drug_general" data-topicid="8473" href="/z/d/drug information/8473.html" rel="external">fluvastatin</a> are the safest statins in this situation [<a href="#rid160">160,171-176</a>] and can be considered for use with gemfibrozil if the benefit is likely to outweigh the risk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">Colchicine</a> – Myopathy is an infrequent adverse effect of colchicine treatment and several cases have been reported following its coadministration with a statin, particularly in the setting of renal insufficiency. Colchicine is metabolized to a substantial degree by CYP3A4 and concurrent use may increase serum concentrations of statins that compete for this metabolic pathway (eg, <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a>, <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">lovastatin</a>, <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a>) [<a href="#rid137">137,177</a>]. However, multiple mechanisms seem to be involved as the interaction has been reported with a variety of statins, including <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">pravastatin</a>, which is not metabolized by CYP3A4 to a clinically significant extent [<a href="#rid178">178-180</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8648" href="/z/d/drug information/8648.html" rel="external">Fusidic acid</a> – Several cases of rhabdomyolysis have been reported following coadministration of <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> or <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a> with fusidic acid, an antimicrobial available primarily outside the United States [<a href="#rid181">181-187</a>]. The interaction appears to cause significant elevation in levels of both the statin and fusidic acid and could be due to inhibition of OATP1B1-mediated hepatic uptake of statins or decreases in biliary efflux [<a href="#rid188">188,189</a>], but the exact mechanism is unknown.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9695" href="/z/d/drug information/9695.html" rel="external">Niacin</a> – Early reports suggested an increased risk of myopathy with combination niacin (nicotinic acid) and statin treatment [<a href="#rid190">190</a>], and this is reflected in longstanding warnings found in some of the statin drug labels [<a href="#rid142">142,150,191</a>]. This complication appears to be uncommon, and the risk of myopathy has seemed similar to that of either agent taken separately [<a href="#rid192">192-194</a>]. However, in a large randomized trial in patients receiving <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a>, the combination of niacin and laropiprant increased the risk of definite myopathy (1.6 versus 0.4 events per 1000 patients per year; risk ratio 4.4, 95% CI 2.6-7.5) [<a href="#rid195">195</a>]. The risk was particularly increased in participants from China (see  <a class="medical medical_review" href="/z/d/html/6833.html" rel="external">"Statin muscle-related adverse events", section on 'Patient characteristics'</a>). It is uncertain whether niacin alone carries the same increased myopathy risk as niacin/laropiprant; however, this trial was much larger than prior studies and had the potential to have detected an interaction between niacin and statins that could have been missed in earlier smaller studies.</p><p></p><p>UpToDate contributors generally avoid administering <a class="drug drug_general" data-topicid="9695" href="/z/d/drug information/9695.html" rel="external">niacin</a> to most patients receiving statin therapy due to concerns about safety and lack of efficacy for clinical endpoints. (See  <a class="medical medical_review" href="/z/d/html/4562.html" rel="external">"Low-density lipoprotein cholesterol lowering with drugs other than statins and PCSK9 inhibitors", section on 'Nicotinic acid (niacin)'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">Clopidogrel</a> – The antiplatelet agent clopidogrel is a prodrug that is activated via metabolism by CYP450. Based on available evidence, clopidogrel therapy need not affect the choice of statin. (See  <a class="medical medical_review" href="/z/d/html/6684.html" rel="external">"Clopidogrel resistance and clopidogrel treatment failure", section on 'Interaction with other drugs'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">Dabigatran</a> – Another potential harmful interaction is that of statin use in patients taking dabigatran. In a study of older patients (80 percent &gt;75 years) taking dabigatran for atrial fibrillation, the use of <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">lovastatin</a> or <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a> was found to be associated with an increased risk of major hemorrhage compared with other statins (odds ratio [OR] 1.46, 95% CI 1.17-1.82) [<a href="#rid196">196</a>]. This has not been observed with other direct oral anticoagulants (DOACs).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">Rifampin</a> – Rifampin has been reported to both increase and decrease statin concentrations, presumably due to a combination of OATP1B1 inhibition and CYP3A4 induction, respectively [<a href="#rid197">197-199</a>]. Patients should be closely monitored for statin efficacy and adverse effects during concurrent rifampin use. Manufacturer labeling for <a class="drug drug_general" data-topicid="9532" href="/z/d/drug information/9532.html" rel="external">pitavastatin</a> recommends dose limitations for coadministration with rifampin [<a href="#rid152">152</a>]; manufacturer labeling for <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> recommends simultaneous coadministration with rifampin to avoid reduced concentrations observed with delayed atorvastatin administration [<a href="#rid151">151</a>].</p><p></p><p class="headingAnchor" id="H3561887587"><span class="h2">Dose limitations</span><span class="headingEndMark"> — </span>Manufacturer labeling for all statins include contraindications or dose limitations for coadministration with a variety of other medications. For example, manufacturer recommendations for <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a> and <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">lovastatin</a>, state that these statins are contraindicated in patients treated with most strong CYP3A4 inhibitors  (<a class="graphic graphic_table graphicRef53730" href="/z/d/graphic/53730.html" rel="external">table 3</a>) and there are dose limitations or recommendations to avoid these statins when used in conjunction with a number of other medications, eg, limitation of simvastatin to 20 mg/day when taken with <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">amlodipine</a> [<a href="#rid56">56,140</a>].</p><p>Given high rates of myopathy with <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a> 80 mg/day [<a href="#rid200">200</a>] and the availability of generic alternatives for high-intensity statin therapy (ie, <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a> and <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a>), we do not treat patients with doses of simvastatin above 40 mg/day. Additionally, clinicians should strongly consider switching patients who are currently tolerating simvastatin 80 mg/day to atorvastatin or rosuvastatin. (See <a class="local">'Potency'</a> above.)</p><p>For more detailed information about dose limitations, refer to the relevant clinical treatment reviews in UpToDate and the individual drug monographs included with UpToDate.</p><p class="headingAnchor" id="H25"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>Routine monitoring of serum creatine kinase (CK) levels is not recommended in patients on statins, but it is useful to obtain a baseline CK level for reference purposes prior to starting statin therapy. Patients treated with statins should be alerted to report the new onset of myalgias or weakness. (See  <a class="medical medical_review" href="/z/d/html/6833.html" rel="external">"Statin muscle-related adverse events", section on 'Monitoring'</a>.)</p><p>We check baseline aminotransferase levels prior to initiating statin therapy; we do not routinely monitor these levels in patients on statins. (See <a class="local">'Hepatic dysfunction'</a> above.)</p><p>Monitoring of the lipid response to statin therapy is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease", section on 'Monitoring therapy'</a>.)</p><p class="headingAnchor" id="H26"><span class="h2">Specific populations</span></p><p class="headingAnchor" id="H3791610959"><span class="h3">Older adults</span><span class="headingEndMark"> — </span>A discussion of dosing in older patients is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease", section on 'Older patients'</a>.)</p><p class="headingAnchor" id="H27"><span class="h3">Chronic kidney disease</span><span class="headingEndMark"> — </span>Chronic kidney disease presents an additional challenge for the selection of a statin. <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">Atorvastatin</a> and <a class="drug drug_general" data-topicid="8473" href="/z/d/drug information/8473.html" rel="external">fluvastatin</a> do not require dose adjustment and are the statins of choice in patients with severe renal impairment [<a href="#rid201">201,202</a>].</p><p>Dose adjustment is warranted with other statins in patients with severe kidney disease (creatinine clearance [CrCl] less than 30 mL/min). If statins other than <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> or <a class="drug drug_general" data-topicid="8473" href="/z/d/drug information/8473.html" rel="external">fluvastatin</a> are used, <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">pravastatin</a> may be safer than other statins. As an example, in a subset analysis of 1711 participants with chronic kidney disease (CrCl ≤75 mL/min) from the CARE trial, treatment with pravastatin for a median of 58.9 months significantly improved outcomes compared with placebo without an increase in side effects [<a href="#rid203">203</a>].</p><p class="headingAnchor" id="H28"><span class="h3">Chronic liver disease</span><span class="headingEndMark"> — </span>Statins need to be used cautiously in patients at high cardiovascular risk with active or chronic liver disease. All statins are metabolized to a certain extent in the liver. However, there is little evidence which can be used to support the use of one agent over another [<a href="#rid204">204,205</a>].</p><p>For this purpose, we define liver disease as unexplained aminotransferase values &gt;3 times above upper normal range confirmed on repeat testing. In addition, statins are contraindicated in patients with decompensated cirrhosis or acute liver failure. The following should be considered when starting statin therapy:</p><p class="bulletIndent1"><span class="glyph">●</span>We ask the patient to completely abstain from alcohol.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We start statin therapy cautiously with a low dose of an agent not extensively metabolized by the liver; <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">pravastatin</a> and <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a> are examples. We then increase the dose based on changes in aminotransferase levels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluate efficacy and impact on aminotransferases in 4 to 12 weeks; the statin dose may be increased if LDL-C remains elevated and aminotransferase levels have not increased further. For patients who do not reach LDL-C goals with this approach and in whom further LDL-C lowering is considered beneficial, we cautiously start a more potent statin and discuss with the patient the potential benefits and risks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Caution is needed in patients with biliary obstructive disease (eg, primary biliary cirrhosis) due to impaired hepatic metabolism of statins and case reports of rhabdomyolysis with <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">lovastatin</a>.</p><p></p><p>If the LDL cholesterol remains elevated, combined therapy with a bile acid sequestrant may allow such patients to achieve their LDL cholesterol target. Statins are contraindicated in patients with progressive liver disease.</p><p>Patients who simply have baseline elevations in aminotransferases do not appear to be at increased risk when prescribed a statin [<a href="#rid48">48</a>]. A study that looked at patients without evidence of alcohol abuse, hepatitis B, or hepatitis C compared a cohort of 342 patients (many of whom presumably had fatty liver or nonalcoholic steatohepatitis) with hyperlipidemia and baseline aminotransferase elevation (AST &gt;40 international units/L [mean 55 international units/L] or alanine aminotransferase [ALT] &gt;35 international units/L [mean 43 international units/L]) who were prescribed a statin with a cohort of 2245 patients with baseline aminotransferase elevation who were not prescribed a statin [<a href="#rid206">206</a>]. There was no significant difference between the cohorts in the incidence of mild to moderate aminotransferase elevations (4.7 versus 6.4 percent) or severe elevations (0.6 versus 0.4 percent). Rates of aminotransferase elevations were also similar in a cohort of hyperlipidemic patients with and without hepatitis C who were prescribed a statin [<a href="#rid207">207</a>].</p><p>A 36-week randomized trial comparing <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">pravastatin</a> 80 mg/day or placebo in 326 patients with well-compensated non-cholestatic chronic liver disease (64 percent with nonalcoholic steatohepatitis; 23 percent with hepatitis C) found similar evidence of safety [<a href="#rid208">208</a>]. Over the course of the trial, rates of aminotransferase elevations were low in the group receiving pravastatin and no different from placebo, and none of the patients had an exacerbation of their underlying liver disease. Similarly, a post hoc analysis of a randomized trial of statin therapy (mainly <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a>, 24 mg/day) found no evidence of increased hepatic risk in patients with moderately abnormal liver function tests at baseline who were treated with a statin [<a href="#rid209">209</a>].</p><p>In a small study of patients with primary biliary cholangitis who were treated with <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a>, significant transaminase elevations were common [<a href="#rid210">210</a>]. Most statins are ultimately excreted in the bile, and toxic levels can develop in patients with cholestasis [<a href="#rid211">211</a>]. Additionally, the standard calculation of LDL cholesterol does not exclude lipoprotein X, which can accumulate in cholestasis but is not atherogenic and so not a target of therapy. While it may be possible to use statins safely in patients with mild cholestasis who have an appropriate indication for therapy [<a href="#rid212">212</a>], we avoid statin therapy in patients with significant cholestasis unless there are compelling indications such as established atherosclerotic vascular disease that is considered clinically important. (See  <a class="medical medical_review" href="/z/d/html/3602.html" rel="external">"Hypercholesterolemia in primary biliary cholangitis (primary biliary cirrhosis)", section on 'Cholesterol metabolism in PBC'</a> and  <a class="medical medical_review" href="/z/d/html/3602.html" rel="external">"Hypercholesterolemia in primary biliary cholangitis (primary biliary cirrhosis)", section on 'Management'</a>.)</p><p>The use of statins is believed to be safe in patients with Gilbert syndrome. (See  <a class="medical medical_review" href="/z/d/html/3578.html" rel="external">"Gilbert syndrome"</a>.)</p><p class="headingAnchor" id="H29"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/15330.html" rel="external">"Patient education: High cholesterol (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/3440.html" rel="external">"Patient education: High cholesterol and lipids (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/3433.html" rel="external">"Patient education: High cholesterol and lipid treatment options (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H30"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – Statins are powerful drugs for lowering low-density lipoprotein (LDL) cholesterol. They have proven benefit in primary and secondary prevention of coronary heart disease but do not improve noncardiovascular disease outcomes. (See <a class="local">'Efficacy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of statin</strong> – The choice of statin depends upon a number of factors, including the degree of hyperlipidemia, pharmacokinetic properties, drug interactions, the presence of renal impairment, and cost.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Potency</strong> – <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">Rosuvastatin</a> and <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> are preferred in patients who require a potent statin because of high cardiovascular risk or who require &gt;35 percent reduction in LDL cholesterol. (See <a class="local">'Potency'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Renal impairment</strong> – In patients with severe renal impairment, we suggest treatment with <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> or <a class="drug drug_general" data-topicid="8473" href="/z/d/drug information/8473.html" rel="external">fluvastatin</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). These medications do not require dose adjustment. (See <a class="local">'Chronic kidney disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic liver disease</strong> – In patients with chronic liver disease who require a statin because of high cardiovascular risk, we suggest complete abstinence from alcohol and the use of <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">pravastatin</a> at a low dose (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Chronic liver disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Drug interactions</strong> – Fewer pharmacokinetic drug interactions are likely to occur with <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">pravastatin</a>, <a class="drug drug_general" data-topicid="8473" href="/z/d/drug information/8473.html" rel="external">fluvastatin</a>, <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">rosuvastatin</a>, and <a class="drug drug_general" data-topicid="9532" href="/z/d/drug information/9532.html" rel="external">pitavastatin</a> because they are not metabolized through the CYP3A4  (<a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">table 4</a>). (See <a class="local">'Drug interactions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Muscle-related adverse events</strong> – There are no clear data that the adverse event profile differs significantly among statins. However, <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">pravastatin</a> and <a class="drug drug_general" data-topicid="8473" href="/z/d/drug information/8473.html" rel="external">fluvastatin</a> appear less likely to cause muscle toxicity than other statins. This problem, including predisposing drug interactions and an approach to management, is discussed elsewhere.  (<a class="graphic graphic_algorithm graphicRef97520" href="/z/d/graphic/97520.html" rel="external">algorithm 1</a>) (See  <a class="medical medical_review" href="/z/d/html/6833.html" rel="external">"Statin muscle-related adverse events"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest not routinely monitoring serum creatine kinase (CK), but it is useful to obtain a baseline CK level for reference purposes prior to starting statin therapy. Patients treated with statins should be alerted to report the new onset of myalgias or weakness. (See  <a class="medical medical_review" href="/z/d/html/6833.html" rel="external">"Statin muscle-related adverse events", section on 'Monitoring'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest checking baseline aminotransferase levels prior to initiating statin therapy; routine monitoring of these levels is not necessary for patients on statins. (See <a class="local">'Hepatic dysfunction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest checking a thyroid-stimulating hormone level prior to initiating statin therapy. (See <a class="local">'Muscle injury'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001; 292:1160.</a></li><li><a class="nounderline abstract_t">Ness GC, Zhao Z, Lopez D. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation. Arch Biochem Biophys 1996; 325:242.</a></li><li><a class="nounderline abstract_t">Conde K, Vergara-Jimenez M, Krause BR, et al. Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig. J Lipid Res 1996; 37:2372.</a></li><li><a class="nounderline abstract_t">Arad Y, Ramakrishnan R, Ginsberg HN. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. J Lipid Res 1990; 31:567.</a></li><li><a class="nounderline abstract_t">Ness GC, Chambers CM, Lopez D. Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity. J Lipid Res 1998; 39:75.</a></li><li><a class="nounderline abstract_t">Larsen ML, Illingworth DR. Drug treatment of dyslipoproteinemia. Med Clin North Am 1994; 78:225.</a></li><li><a class="nounderline abstract_t">Levy RI, Troendle AJ, Fattu JM. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation 1993; 87:III45.</a></li><li><a class="nounderline abstract_t">Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med 1994; 154:1586.</a></li><li><a class="nounderline abstract_t">Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81:582.</a></li><li><a class="nounderline abstract_t">Rosenson RS. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther 2003; 1:495.</a></li><li><a class="nounderline abstract_t">Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92:152.</a></li><li><a class="nounderline abstract_t">Brown AS, Bakker-Arkema RG, Yellen L, et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol 1998; 32:665.</a></li><li><a class="nounderline abstract_t">Eidelman RS, Lamas GA, Hennekens CH. The new National Cholesterol Education Program guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease. Arch Intern Med 2002; 162:2033.</a></li><li class="breakAll">www.fda.gov/Drugs/DrugSafety/ucm256581.htm (Accessed on March 15, 2013).</li><li><a class="nounderline abstract_t">Sprecher DL, Abrams J, Allen JW, et al. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med 1994; 120:537.</a></li><li><a class="nounderline abstract_t">Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323:1289.</a></li><li><a class="nounderline abstract_t">Pan HY, DeVault AR, Swites BJ, et al. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther 1990; 48:201.</a></li><li><a class="nounderline abstract_t">Rosenson RS, Otvos JD, Hsia J. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. Diabetes Care 2009; 32:1087.</a></li><li><a class="nounderline abstract_t">März W, Scharnagl H, Abletshauser C, et al. Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype. Circulation 2001; 103:1942.</a></li><li><a class="nounderline abstract_t">Otvos JD, Shalaurova I, Freedman DS, Rosenson RS. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis 2002; 160:41.</a></li><li><a class="nounderline abstract_t">Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286:64.</a></li><li><a class="nounderline abstract_t">Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. J Lipid Res 2010; 51:1546.</a></li><li><a class="nounderline abstract_t">Niesor EJ, Schwartz GG, Perez A, et al. Statin-induced decrease in ATP-binding cassette transporter A1 expression via microRNA33 induction may counteract cholesterol efflux to high-density lipoprotein. Cardiovasc Drugs Ther 2015; 29:7.</a></li><li><a class="nounderline abstract_t">Rosenson RS, Brewer HB Jr. New challenges for HDL-modifying therapies as a strategy to lower cardiovascular disease events in statin-treated patients. Cardiovasc Drugs Ther 2015; 29:1.</a></li><li><a class="nounderline abstract_t">Nicholls SJ, Ruotolo G, Brewer HB, et al. Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib. J Am Coll Cardiol 2015; 66:2201.</a></li><li><a class="nounderline abstract_t">Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996; 275:128.</a></li><li><a class="nounderline abstract_t">Davidson M, McKenney J, Stein E, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol 1997; 79:1475.</a></li><li><a class="nounderline abstract_t">Dart A, Jerums G, Nicholson G, et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997; 80:39.</a></li><li><a class="nounderline abstract_t">Mulder AB, van Lijf HJ, Bon MA, et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin Pharmacol Ther 2001; 70:546.</a></li><li><a class="nounderline abstract_t">Chasman DI, Posada D, Subrahmanyan L, et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004; 291:2821.</a></li><li><a class="nounderline abstract_t">Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol 2007; 99:410.</a></li><li class="breakAll">www.astrazeneca-us.com/pi/crestor.pdf (Accessed on February 08, 2007).</li><li><a class="nounderline abstract_t">He Y, Li X, Gasevic D, et al. Statins and Multiple Noncardiovascular Outcomes: Umbrella Review of Meta-analyses of Observational Studies and Randomized Controlled Trials. Ann Intern Med 2018; 169:543.</a></li><li><a class="nounderline abstract_t">Rosenson RS, Baker SK, Jacobson TA, et al. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol 2014; 8:S58.</a></li><li><a class="nounderline abstract_t">Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015; 36:1012.</a></li><li><a class="nounderline abstract_t">Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006; 114:2788.</a></li><li><a class="nounderline abstract_t">Armitage J. The safety of statins in clinical practice. Lancet 2007; 370:1781.</a></li><li><a class="nounderline abstract_t">Riaz H, Khan AR, Khan MS, et al. Meta-analysis of Placebo-Controlled Randomized Controlled Trials on the Prevalence of Statin Intolerance. Am J Cardiol 2017; 120:774.</a></li><li><a class="nounderline abstract_t">Gupta A, Thompson D, Whitehouse A, et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 2017; 389:2473.</a></li><li><a class="nounderline abstract_t">Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004; 116:408.</a></li><li><a class="nounderline abstract_t">Brewer HB Jr. Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003; 92:23K.</a></li><li><a class="nounderline abstract_t">Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther 2005; 19:403.</a></li><li><a class="nounderline abstract_t">Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med 2013; 158:526.</a></li><li><a class="nounderline abstract_t">Zhang H, Plutzky J, Shubina M, Turchin A. Continued Statin Prescriptions After Adverse Reactions and Patient Outcomes: A Cohort Study. Ann Intern Med 2017; 167:221.</a></li><li><a class="nounderline abstract_t">Serban MC, Colantonio LD, Manthripragada AD, et al. Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. J Am Coll Cardiol 2017; 69:1386.</a></li><li><a class="nounderline abstract_t">Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol 2012; 56:374.</a></li><li><a class="nounderline abstract_t">Russo MW, Hoofnagle JH, Gu J, et al. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology 2014; 60:679.</a></li><li><a class="nounderline abstract_t">Cohen DE, Anania FA, Chalasani N, National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol 2006; 97:77C.</a></li><li><a class="nounderline abstract_t">Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615.</a></li><li><a class="nounderline abstract_t">Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383.</a></li><li><a class="nounderline abstract_t">Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7.</a></li><li><a class="nounderline abstract_t">Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 2002; 105:2341.</a></li><li><a class="nounderline abstract_t">Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010; 340:c2197.</a></li><li><a class="nounderline abstract_t">Smith CC, Bernstein LI, Davis RB, et al. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med 2003; 163:688.</a></li><li><a class="nounderline abstract_t">Charles EC, Olson KL, Sandhoff BG, et al. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med 2005; 118:618.</a></li><li class="breakAll">US Food and Drug Administration. FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. February 28, 2012. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm (Accessed on February 28, 2012).</li><li><a class="nounderline abstract_t">Weismantel D, Danis P. Clinical inquiries. What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents? J Fam Pract 2001; 50:927.</a></li><li><a class="nounderline abstract_t">Gotto AM Jr. Safety and statin therapy: reconsidering the risks and benefits. Arch Intern Med 2003; 163:657.</a></li><li><a class="nounderline abstract_t">Bar SL, Holmes DT, Frohlich J. Asymptomatic hypothyroidism and statin-induced myopathy. Can Fam Physician 2007; 53:428.</a></li><li><a class="nounderline abstract_t">Lando HM, Burman KD. Two cases of statin-induced myopathy caused by induced hypothyroidism. Endocr Pract 2008; 14:726.</a></li><li><a class="nounderline abstract_t">Vidt DG, Cressman MD, Harris S, et al. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004; 102:52.</a></li><li><a class="nounderline abstract_t">Sidaway JE, Davidson RG, McTaggart F, et al. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol 2004; 15:2258.</a></li><li><a class="nounderline abstract_t">Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 2005; 111:3051.</a></li><li><a class="nounderline abstract_t">Grundy SM. The issue of statin safety: where do we stand? Circulation 2005; 111:3016.</a></li><li class="breakAll">www.fda.gov/cder/drug/infopage/rosuvastatin/crestor_CP.pdf (Accessed on June 10, 2005).</li><li><a class="nounderline abstract_t">McAfee AT, Ming EE, Seeger JD, et al. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. Pharmacoepidemiol Drug Saf 2006; 15:444.</a></li><li><a class="nounderline abstract_t">Guthrie RM, Martin DR. The safety of rosuvastatin: effects on renal and hepatic function. Expert Opin Drug Saf 2007; 6:573.</a></li><li><a class="nounderline abstract_t">García-Rodríguez LA, Massó-González EL, Wallander MA, Johansson S. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care. Pharmacoepidemiol Drug Saf 2008; 17:943.</a></li><li><a class="nounderline abstract_t">García-Rodríguez LA, González-Pérez A, Stang MR, et al. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases. Pharmacoepidemiol Drug Saf 2008; 17:953.</a></li><li><a class="nounderline abstract_t">Shin JI, Fine DM, Sang Y, et al. Association of Rosuvastatin Use with Risk of Hematuria and Proteinuria. J Am Soc Nephrol 2022; 33:1767.</a></li><li><a class="nounderline abstract_t">Dormuth CR, Hemmelgarn BR, Paterson JM, et al. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ 2013; 346:f880.</a></li><li><a class="nounderline abstract_t">Bangalore S, Fayyad R, Hovingh GK, et al. Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials. Am J Cardiol 2014; 113:2018.</a></li><li><a class="nounderline abstract_t">Yang CC, Jick SS, Jick H. Lipid-lowering drugs and the risk of depression and suicidal behavior. Arch Intern Med 2003; 163:1926.</a></li><li><a class="nounderline abstract_t">Golomb BA, Kane T, Dimsdale JE. Severe irritability associated with statin cholesterol-lowering drugs. QJM 2004; 97:229.</a></li><li><a class="nounderline abstract_t">Redelmeier DA, Thiruchelvam D, Daneman N. Delirium after elective surgery among elderly patients taking statins. CMAJ 2008; 179:645.</a></li><li><a class="nounderline abstract_t">Marcantonio ER. Statins and postoperative delirium. CMAJ 2008; 179:627.</a></li><li class="breakAll">CGS News www.cbsnews.com/stories/2004/05/24/eveningnews/main619351.shtml (Accessed on March 07, 2005).</li><li class="breakAll">Graveline D. Lipitor: Thief of memory: Statin Drugs and the Misguided War on Cholesterol, Infinity Publishing, Haverford, PA 2004.</li><li><a class="nounderline abstract_t">Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003; 23:871.</a></li><li><a class="nounderline abstract_t">Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med 2000; 108:538.</a></li><li><a class="nounderline abstract_t">Muldoon MF, Ryan CM, Sereika SM, et al. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med 2004; 117:823.</a></li><li><a class="nounderline abstract_t">Richardson K, Schoen M, French B, et al. Statins and cognitive function: a systematic review. Ann Intern Med 2013; 159:688.</a></li><li><a class="nounderline abstract_t">Ott BR, Daiello LA, Dahabreh IJ, et al. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med 2015; 30:348.</a></li><li><a class="nounderline abstract_t">Strom BL, Schinnar R, Karlawish J, et al. Statin Therapy and Risk of Acute Memory Impairment. JAMA Intern Med 2015; 175:1399.</a></li><li><a class="nounderline abstract_t">Rojas-Fernandez CH, Cameron JC. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother 2012; 46:549.</a></li><li><a class="nounderline abstract_t">Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012; 380:565.</a></li><li><a class="nounderline abstract_t">Wang KL, Liu CJ, Chao TF, et al. Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol 2012; 60:1231.</a></li><li><a class="nounderline abstract_t">Yu Y, Ohmori K, Chen Y, et al. Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. J Am Coll Cardiol 2004; 44:904.</a></li><li><a class="nounderline abstract_t">Wong V, Stavar L, Szeto L, et al. Atorvastatin induces insulin sensitization in Zucker lean and fatty rats. Atherosclerosis 2006; 184:348.</a></li><li><a class="nounderline abstract_t">Chen Y, Ohmori K, Mizukawa M, et al. Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes. Circ J 2007; 71:144.</a></li><li><a class="nounderline abstract_t">Mita T, Watada H, Nakayama S, et al. Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia. Endocr J 2007; 54:441.</a></li><li><a class="nounderline abstract_t">Yamakawa T, Takano T, Tanaka S, et al. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2008; 15:269.</a></li><li><a class="nounderline abstract_t">Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J Clin Endocrinol Metab 2009; 94:103.</a></li><li><a class="nounderline abstract_t">Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103:357.</a></li><li><a class="nounderline abstract_t">Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195.</a></li><li class="breakAll">Shepherd J. Glasgow Royal Infirmary, 2008, personal communication.</li><li><a class="nounderline abstract_t">Coleman CI, Reinhart K, Kluger J, White CM. The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2008; 24:1359.</a></li><li><a class="nounderline abstract_t">Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375:735.</a></li><li><a class="nounderline abstract_t">Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011; 305:2556.</a></li><li><a class="nounderline abstract_t">Carter AA, Gomes T, Camacho X, et al. Risk of incident diabetes among patients treated with statins: population based study. BMJ 2013; 346:f2610.</a></li><li><a class="nounderline abstract_t">Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015; 385:351.</a></li><li><a class="nounderline abstract_t">Frayling TM. Statins and type 2 diabetes: genetic studies on target. Lancet 2015; 385:310.</a></li><li><a class="nounderline abstract_t">Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388:2532.</a></li><li><a class="nounderline abstract_t">Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267.</a></li><li><a class="nounderline abstract_t">Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis. JAMA 2006; 295:74.</a></li><li><a class="nounderline abstract_t">Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007; 120:833.</a></li><li><a class="nounderline abstract_t">Cholesterol Treatment Trialists' (CTT) Collaboration, Emberson JR, Kearney PM, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 2012; 7:e29849.</a></li><li><a class="nounderline abstract_t">Strandberg TE, Pyörälä K, Cook TJ, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004; 364:771.</a></li><li><a class="nounderline abstract_t">Ford I, Murray H, Packard CJ, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007; 357:1477.</a></li><li><a class="nounderline abstract_t">Heart Protection Study Collaborative Group, Bulbulia R, Bowman L, et al. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet 2011; 378:2013.</a></li><li><a class="nounderline abstract_t">Pursnani A, Massaro JM, D'Agostino RB Sr, et al. Guideline-Based Statin Eligibility, Cancer Events, and Noncardiovascular Mortality in the Framingham Heart Study. J Clin Oncol 2017; 35:2927.</a></li><li><a class="nounderline abstract_t">Schlienger RG, Haefeli WE, Jick H, Meier CR. Risk of cataract in patients treated with statins. Arch Intern Med 2001; 161:2021.</a></li><li><a class="nounderline abstract_t">Smeeth L, Hubbard R, Fletcher AE. Cataract and the use of statins: a case-control study. QJM 2003; 96:337.</a></li><li><a class="nounderline abstract_t">Klein BE, Klein R, Lee KE, Grady LM. Statin use and incident nuclear cataract. JAMA 2006; 295:2752.</a></li><li><a class="nounderline abstract_t">Harris ML, Bron AJ, Brown NA, et al. Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group. Br J Ophthalmol 1995; 79:996.</a></li><li><a class="nounderline abstract_t">Leuschen J, Mortensen EM, Frei CR, et al. Association of statin use with cataracts: a propensity score-matched analysis. JAMA Ophthalmol 2013; 131:1427.</a></li><li><a class="nounderline abstract_t">Bang CN, Greve AM, La Cour M, et al. Effect of Randomized Lipid Lowering With Simvastatin and Ezetimibe on Cataract Development (from the Simvastatin and Ezetimibe in Aortic Stenosis Study). Am J Cardiol 2015; 116:1840.</a></li><li><a class="nounderline abstract_t">Warendorf JK, Vrancken AFJE, van Eijk RPA, et al. Statins do not increase risk of polyneuropathy: A case-control study and literature review. Neurology 2019; 92:e2136.</a></li><li><a class="nounderline abstract_t">Dobs AS, Schrott H, Davidson MH, et al. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism 2000; 49:1234.</a></li><li><a class="nounderline abstract_t">Davidson MH, Stein EA, Dujovne CA, et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 1997; 79:38.</a></li><li><a class="nounderline abstract_t">Azzarito C, Boiardi L, Vergoni W, et al. Testicular function in hypercholesterolemic male patients during prolonged simvastatin treatment. Horm Metab Res 1996; 28:193.</a></li><li><a class="nounderline abstract_t">Santini SA, Carrozza C, Lulli P, et al. Atorvastatin treatment does not affect gonadal and adrenal hormones in type 2 diabetes patients with mild to moderate hypercholesterolemia. J Atheroscler Thromb 2003; 10:160.</a></li><li class="breakAll">US Food and Drug Administration. FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy; still advises most pregnant patients should stop taking statins. July 2021. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy (Accessed on July 20, 2021).</li><li><a class="nounderline abstract_t">Miettinen TA. Diurnal variation of cholesterol precursors squalene and methyl sterols in human plasma lipoproteins. J Lipid Res 1982; 23:466.</a></li><li><a class="nounderline abstract_t">Saito Y, Yoshida S, Nakaya N, et al. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study. Arterioscler Thromb 1991; 11:816.</a></li><li><a class="nounderline abstract_t">Wallace A, Chinn D, Rubin G. Taking simvastatin in the morning compared with in the evening: randomised controlled trial. BMJ 2003; 327:788.</a></li><li><a class="nounderline abstract_t">Cilla DD Jr, Gibson DM, Whitfield LR, Sedman AJ. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol 1996; 36:604.</a></li><li><a class="nounderline abstract_t">Rindone JP, Hiller D, Arriola G. A comparison of fluvastatin 40 mg every other day versus 20 mg every day in patients with hypercholesterolemia. Pharmacotherapy 1998; 18:836.</a></li><li><a class="nounderline abstract_t">Matalka MS, Ravnan MC, Deedwania PC. Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS). Am Heart J 2002; 144:674.</a></li><li><a class="nounderline abstract_t">Jafari M, Ebrahimi R, Ahmadi-Kashani M, et al. Efficacy of alternate-day dosing versus daily dosing of atorvastatin. J Cardiovasc Pharmacol Ther 2003; 8:123.</a></li><li><a class="nounderline abstract_t">Ferrer-García JC, Pérez-Silvestre J, Martínez-Mir I, Herrera-Ballester A. Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidaemia. Acta Diabetol 2006; 43:75.</a></li><li><a class="nounderline abstract_t">Wongwiwatthananukit S, Sansanayudh N, Dhummauppakorn R, Kitiyadisai C. Efficacy and safety of rosuvastatin every other day compared with once daily in patients with hypercholesterolemia. Ann Pharmacother 2006; 40:1917.</a></li><li><a class="nounderline abstract_t">Backes JM, Venero CV, Gibson CA, et al. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother 2008; 42:341.</a></li><li><a class="nounderline abstract_t">Kayikçioğlu M, Ozerkan F, Soydan I. Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia. Am J Cardiol 1999; 83:1135.</a></li><li><a class="nounderline abstract_t">Ruisinger JF, Backes JM, Gibson CA, Moriarty PM. Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. Am J Cardiol 2009; 103:393.</a></li><li><a class="nounderline abstract_t">Drugs for lipids. Treat Guidel Med Lett 2008; 6:9.</a></li><li><a class="nounderline abstract_t">Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 2016; 134:e468.</a></li><li><a class="nounderline abstract_t">Chatzizisis YS, Koskinas KC, Misirli G, et al. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 2010; 33:171.</a></li><li><a class="nounderline abstract_t">FDC Reports. The Pink Sheet 2002; 64:5.</a></li><li class="breakAll">Simvastatin [package insert]. Basking Ridge, NJ: Micro Labs Limited; 2020. Available at: https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=5c1c694c-4b08-469e-b538-08e69df06146&amp;type=pdf (Accessed on August 10, 2020).</li><li><a class="nounderline abstract_t">Penzak SR, Chuck SK. Management of protease inhibitor-associated hyperlipidemia. Am J Cardiovasc Drugs 2002; 2:91.</a></li><li class="breakAll">Lovastatin [package insert]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme Corp; Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019643s085lbl.pdf (Accessed on July 30, 2020).</li><li><a class="nounderline abstract_t">Becquemont L, Neuvonen M, Verstuyft C, et al. Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. Clin Pharmacol Ther 2007; 81:679.</a></li><li><a class="nounderline abstract_t">Schmidt GA, Hoehns JD, Purcell JL, et al. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir. J Am Board Fam Med 2007; 20:411.</a></li><li><a class="nounderline abstract_t">Roten L, Schoenenberger RA, Krähenbühl S, Schlienger RG. Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother 2004; 38:978.</a></li><li><a class="nounderline abstract_t">Marot A, Morelle J, Chouinard VA, et al. Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature. Acta Clin Belg 2011; 66:134.</a></li><li><a class="nounderline abstract_t">Reddy P, Ellington D, Zhu Y, et al. Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. Br J Clin Pharmacol 2011; 72:434.</a></li><li><a class="nounderline abstract_t">Lilja JJ, Neuvonen M, Neuvonen PJ. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol 2004; 58:56.</a></li><li><a class="nounderline abstract_t">Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009; 158:693.</a></li><li class="breakAll">Rosuvastatin [package insert]. AstraZeneca; 2010. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021366s016lbl.pdf (Accessed on July 31, 2020).</li><li class="breakAll">Atorvastatin [package insert]. Pfizer; 2009. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020702s056lbl.pdf (Accessed on July 31, 2020).</li><li class="breakAll">Pitavastatin [package insert]. Kowa Pharmaceuticals America; 2009. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022363s000lbl.pdf (Accessed on July 31, 2020).</li><li><a class="nounderline abstract_t">Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988; 62:28J.</a></li><li><a class="nounderline abstract_t">Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988; 319:24.</a></li><li><a class="nounderline abstract_t">Keogh A, Macdonald P, Kaan A, et al. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 2000; 19:529.</a></li><li><a class="nounderline abstract_t">Shitara Y, Maeda K, Ikejiri K, et al. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos 2013; 34:45.</a></li><li class="breakAll">Simeprevir [package insert]. Janssen; 2013. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205123s001lbl.pdf (Accessed on July 31, 2020).</li><li class="breakAll">Viekira pak [package insert]. AbbVie; 2014. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206619lbl.pdf (Accessed on July 31, 2020).</li><li><a class="nounderline abstract_t">Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292:2585.</a></li><li><a class="nounderline abstract_t">Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997; 80:608.</a></li><li><a class="nounderline abstract_t">Ellen RL, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol 1998; 81:60B.</a></li><li><a class="nounderline abstract_t">Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur Heart J 1995; 16:5.</a></li><li><a class="nounderline abstract_t">Ballantyne CM, Davidson MH. Possible differences between fibrates in pharmacokinetic interactions with statins. Arch Intern Med 2003; 163:2394.</a></li><li><a class="nounderline abstract_t">Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002; 301:1042.</a></li><li><a class="nounderline abstract_t">Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849.</a></li><li><a class="nounderline abstract_t">Geng Q, Ren J, Chen H, et al. Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials. Clin Exp Pharmacol Physiol 2013; 40:219.</a></li><li><a class="nounderline abstract_t">Guo J, Meng F, Ma N, et al. Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia. Am J Cardiol 2012; 110:1296.</a></li><li><a class="nounderline abstract_t">Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264:71.</a></li><li><a class="nounderline abstract_t">Glueck CJ, Oakes N, Speirs J, et al. Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias. Am J Cardiol 1992; 70:1.</a></li><li><a class="nounderline abstract_t">Duell PB, Connor WE, Illingworth DR. Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol 1998; 81:368.</a></li><li><a class="nounderline abstract_t">Spence JD, Munoz CE, Hendricks L, et al. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 1995; 76:80A.</a></li><li><a class="nounderline abstract_t">Noé J, Portmann R, Brun ME, Funk C. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 2007; 35:1308.</a></li><li><a class="nounderline abstract_t">Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993; 94:13.</a></li><li><a class="nounderline abstract_t">Rosenson RS, Frauenheim WA. Safety of combined pravastatin-gemfibrozil therapy. Am J Cardiol 1994; 74:499.</a></li><li><a class="nounderline abstract_t">Farnier M, Dejager S. Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group. Am J Cardiol 2000; 85:53.</a></li><li><a class="nounderline abstract_t">Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 2003; 73:538.</a></li><li><a class="nounderline abstract_t">Tateishi T, Soucek P, Caraco Y, et al. Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation. Biochem Pharmacol 1997; 53:111.</a></li><li><a class="nounderline abstract_t">Baker SK, Goodwin S, Sur M, Tarnopolsky MA. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle Nerve 2004; 30:799.</a></li><li><a class="nounderline abstract_t">Alayli G, Cengiz K, Cantürk F, et al. Acute myopathy in a patient with concomitant use of pravastatin and colchicine. Ann Pharmacother 2005; 39:1358.</a></li><li class="breakAll">Pravastatin sodium [package insert]. Bristol-Myers Squibb; 1991. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019898s062lbl.pdf (Accessed on July 31, 2020).</li><li><a class="nounderline abstract_t">Kotanko P, Kirisits W, Skrabal F. Rhabdomyolysis and acute renal graft impairment in a patient treated with simvastatin, tacrolimus, and fusidic acid. Nephron 2002; 90:234.</a></li><li><a class="nounderline abstract_t">Wenisch C, Krause R, Fladerer P, et al. Acute rhabdomyolysis after atorvastatin and fusidic acid therapy. Am J Med 2000; 109:78.</a></li><li><a class="nounderline abstract_t">Yuen SL, McGarity B. Rhabdomyolysis secondary to interaction of fusidic acid and simvastatin. Med J Aust 2003; 179:172.</a></li><li><a class="nounderline abstract_t">Magee CN, Medani SA, Leavey SF, et al. Severe rhabdomyolysis as a consequence of the interaction of fusidic acid and atorvastatin. Am J Kidney Dis 2010; 56:e11.</a></li><li><a class="nounderline abstract_t">O'Mahony C, Campbell VL, Al-Khayatt MS, Brull DJ. Rhabdomyolysis with atorvastatin and fusidic acid. Postgrad Med J 2008; 84:325.</a></li><li><a class="nounderline abstract_t">Burtenshaw AJ, Sellors G, Downing R. Presumed interaction of fusidic acid with simvastatin. Anaesthesia 2008; 63:656.</a></li><li><a class="nounderline abstract_t">Kearney S, Carr AS, McConville J, et al. Rhabdomyolysis after co-prescription of statin and fusidic acid. BMJ 2012; 345:e6562.</a></li><li><a class="nounderline abstract_t">Eng H, Scialis RJ, Rotter CJ, et al. The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. Drug Metab Dispos 2016; 44:692.</a></li><li><a class="nounderline abstract_t">Bode KA, Donner MG, Leier I, Keppler D. Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. Biochem Pharmacol 2002; 64:151.</a></li><li><a class="nounderline abstract_t">Reaven P, Witztum JL. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med 1988; 109:597.</a></li><li class="breakAll">Pravastatin sodium [package insert]. Silver Spring, MD: Bristol-Myers Squibb Company; Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/019898Orig1s061.pdf (Accessed on December 14, 2020).</li><li><a class="nounderline abstract_t">Guyton JR, Capuzzi DM. Treatment of hyperlipidemia with combined niacin-statin regimens. Am J Cardiol 1998; 82:82U.</a></li><li><a class="nounderline abstract_t">Bays H. Safety of niacin and simvastatin combination therapy. Am J Cardiol 2008; 101:3B.</a></li><li><a class="nounderline abstract_t">Karas RH, Kashyap ML, Knopp RH, et al. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs 2008; 8:69.</a></li><li><a class="nounderline abstract_t">HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013; 34:1279.</a></li><li><a class="nounderline abstract_t">Antoniou T, Macdonald EM, Yao Z, et al. Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. CMAJ 2017; 189:E4.</a></li><li><a class="nounderline abstract_t">Lau YY, Huang Y, Frassetto L, Benet LZ. effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 2007; 81:194.</a></li><li><a class="nounderline abstract_t">He YJ, Zhang W, Chen Y, et al. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T&gt;C polymorphism. Clin Chim Acta 2009; 405:49.</a></li><li><a class="nounderline abstract_t">Kyrklund C, Backman JT, Kivistö KT, et al. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 2000; 68:592.</a></li><li class="breakAll">US Food and Drug Administration. FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-restrictions-contraindications-and-dose-limitations-zocor (Accessed on July 31, 2020).</li><li><a class="nounderline abstract_t">Chong PH, Seeger JD, Franklin C. Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med 2001; 111:390.</a></li><li><a class="nounderline abstract_t">Kasiske BL, Wanner C, O'Neill WC, National Lipid Association Statin Safety Task Force Kidney Expert Panel. An assessment of statin safety by nephrologists. Am J Cardiol 2006; 97:82C.</a></li><li><a class="nounderline abstract_t">Tonelli M, Moyé L, Sacks FM, et al. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003; 138:98.</a></li><li><a class="nounderline abstract_t">Kim H, Lee H, Kim TM, et al. Change in ALT levels after administration of HMG-CoA reductase inhibitors to subjects with pretreatment levels three times the upper normal limit in clinical practice. Cardiovasc Ther 2018; 36:e12324.</a></li><li><a class="nounderline abstract_t">Imprialos KP, Stavropoulos K, Doumas M, et al. The potential role of statins in treating liver disease. Expert Rev Gastroenterol Hepatol 2018; 12:331.</a></li><li><a class="nounderline abstract_t">Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004; 126:1287.</a></li><li><a class="nounderline abstract_t">Khorashadi S, Hasson NK, Cheung RC. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol 2006; 4:902.</a></li><li><a class="nounderline abstract_t">Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007; 46:1453.</a></li><li><a class="nounderline abstract_t">Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376:1916.</a></li><li><a class="nounderline abstract_t">Stojakovic T, Putz-Bankuti C, Fauler G, et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 2007; 46:776.</a></li><li><a class="nounderline abstract_t">Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis 2007; 194:293.</a></li><li><a class="nounderline abstract_t">Abu Rajab M, Kaplan MM. Statins in primary biliary cirrhosis: are they safe? Dig Dis Sci 2010; 55:2086.</a></li></ol></div><div id="topicVersionRevision">Topic 4564 Version 94.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11349148" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Structural mechanism for statin inhibition of HMG-CoA reductase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8561503" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8978489" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2351867" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9469588" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8283933" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Drug treatment of dyslipoproteinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8462180" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8031206" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9514454" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15030249" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12860216" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9741509" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12374510" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The new National Cholesterol Education Program guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12374510" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The new National Cholesterol Education Program guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8093139" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2215615" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2116260" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19265025" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11306521" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11755921" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11434828" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19965573" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25749868" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Statin-induced decrease in ATP-binding cassette transporter A1 expression via microRNA33 induction may counteract cholesterol efflux to high-density lipoprotein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25702643" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : New challenges for HDL-modifying therapies as a strategy to lower cardiovascular disease events in statin-treated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26564598" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8531308" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9185636" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9205017" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11753271" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15199031" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pharmacogenetic study of statin therapy and cholesterol reduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17261409" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Safety and efficacy of statins in Asians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17261409" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Safety and efficacy of statins in Asians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30304368" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Statins and Multiple Noncardiovascular Outcomes: Umbrella Review of Meta-analyses of Observational Studies and Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24793443" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : An assessment by the Statin Muscle Safety Task Force: 2014 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25694464" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17159064" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Risks associated with statin therapy: a systematic overview of randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17559928" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The safety of statins in clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28779871" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Meta-analysis of Placebo-Controlled Randomized Controlled Trials on the Prevalence of Statin Intolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28476288" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15006590" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Current overview of statin-induced myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12948873" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16453090" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23546564" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Discontinuation of statins in routine care settings: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28738423" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Continued Statin Prescriptions After Adverse Reactions and Patient Outcomes: A Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28302290" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21889469" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24700436" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16581333" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : An assessment of statin safety by hepatologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9613910" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7968073" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12114036" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12021218" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20488911" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12639201" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15922693" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15922693" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11711005" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Clinical inquiries. What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12639194" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Safety and statin therapy: reconsidering the risks and benefits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17872677" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Asymptomatic hypothyroidism and statin-induced myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18996793" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Two cases of statin-induced myopathy caused by induced hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15073451" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Rosuvastatin-induced arrest in progression of renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15339975" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15911706" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15911705" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The issue of statin safety: where do we stand?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15911705" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The issue of statin safety: where do we stand?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16761308" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17877444" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The safety of rosuvastatin: effects on renal and hepatic function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18425988" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18425987" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35853713" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Association of Rosuvastatin Use with Risk of Hematuria and Proteinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23511950" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24793673" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12963565" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Lipid-lowering drugs and the risk of depression and suicidal behavior.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15028853" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Severe irritability associated with statin cholesterol-lowering drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18809895" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Delirium after elective surgery among elderly patients taking statins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18809885" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Statins and postoperative delirium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18809885" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Statins and postoperative delirium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18809885" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Statins and postoperative delirium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12885101" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Statin-associated memory loss: analysis of 60 case reports and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10806282" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Effects of lovastatin on cognitive function and psychological well-being.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15589485" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24247674" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Statins and cognitive function: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25575908" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26054031" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Statin Therapy and Risk of Acute Memory Impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22474137" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22883507" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22884288" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Statins, risk of diabetes, and implications on outcomes in the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15312879" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15998521" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Atorvastatin induces insulin sensitization in Zucker lean and fatty rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17186993" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17457013" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18981652" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18940877" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157685" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18997196" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18997196" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18384710" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20167359" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21693744" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23704171" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Risk of incident diabetes among patients treated with statins: population based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25262344" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25262342" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Statins and type 2 diabetes: genetic studies on target.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27616593" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Interpretation of the evidence for the efficacy and safety of statin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16214597" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16391219" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Statins and cancer risk: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17131313" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Statins and risk of cancer: a systematic review and metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22276132" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15337403" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17928595" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Long-term follow-up of the West of Scotland Coronary Prevention Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22115874" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28700275" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Guideline-Based Statin Eligibility, Cancer Events, and Noncardiovascular Mortality in the Framingham Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11525705" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Risk of cataract in patients treated with statins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12702782" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Cataract and the use of statins: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16788130" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Statin use and incident nuclear cataract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8534671" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24052188" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Association of statin use with cataracts: a propensity score-matched analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26602073" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Effect of Randomized Lipid Lowering With Simvastatin and Ezetimibe on Cataract Development (from the Simvastatin and Ezetimibe in Aortic Stenosis Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30737334" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Statins do not increase risk of polyneuropathy: A case-control study and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11016911" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9024733" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8740196" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Testicular function in hypercholesterolemic male patients during prolonged simvastatin treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14564085" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Atorvastatin treatment does not affect gonadal and adrenal hormones in type 2 diabetes patients with mild to moderate hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14564085" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Atorvastatin treatment does not affect gonadal and adrenal hormones in type 2 diabetes patients with mild to moderate hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7200504" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Diurnal variation of cholesterol precursors squalene and methyl sterols in human plasma lipoproteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2065035" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14525878" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Taking simvastatin in the morning compared with in the evening: randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8844442" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9692657" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : A comparison of fluvastatin 40 mg every other day versus 20 mg every day in patients with hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12360164" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12808485" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Efficacy of alternate-day dosing versus daily dosing of atorvastatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17143784" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17003082" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Efficacy and safety of rosuvastatin every other day compared with once daily in patients with hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18285559" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10190536" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19166695" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18216759" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Drugs for lipids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27754879" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20158283" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : </p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : </p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14727985" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Management of protease inhibitor-associated hyperlipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14727985" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Management of protease inhibitor-associated hyperlipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17301736" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17615423" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15069169" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Rhabdomyolysis in association with simvastatin and amiodarone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21630612" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21501216" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15206993" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19785645" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Impact of OATP transporters on pharmacokinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19785645" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Impact of OATP transporters on pharmacokinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19785645" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Impact of OATP transporters on pharmacokinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19785645" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Impact of OATP transporters on pharmacokinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3055921" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Efficacy and long-term adverse effect pattern of lovastatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3288867" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : HMG-CoA reductase inhibitors for treatment of hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10867332" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23115084" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23115084" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23115084" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15572716" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9294990" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9526816" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7737222" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14581261" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Possible differences between fibrates in pharmacokinetic interactions with statins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12023536" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Mechanistic studies on metabolic interactions between gemfibrozil and statins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16310551" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23324122" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22840347" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2355431" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1615846" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9468088" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Rhabdomyolysis after taking atorvastatin with gemfibrozil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7604806" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Pharmacokinetics of the combination of fluvastatin and gemfibrozil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17470528" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8420296" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8059735" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Safety of combined pravastatin-gemfibrozil therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11078237" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12811363" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8960070" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15389652" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Cytoskeletal myotoxicity from simvastatin and colchicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15914514" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Acute myopathy in a patient with concomitant use of pravastatin and colchicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15914514" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Acute myopathy in a patient with concomitant use of pravastatin and colchicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11818715" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Rhabdomyolysis and acute renal graft impairment in a patient treated with simvastatin, tacrolimus, and fusidic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10991749" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Acute rhabdomyolysis after atorvastatin and fusidic acid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12885276" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Rhabdomyolysis secondary to interaction of fusidic acid and simvastatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20888103" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Severe rhabdomyolysis as a consequence of the interaction of fusidic acid and atorvastatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18644925" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Rhabdomyolysis with atorvastatin and fusidic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18477279" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Presumed interaction of fusidic acid with simvastatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23047962" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Rhabdomyolysis after co-prescription of statin and fusidic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26888941" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12106615" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3421570" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Lovastatin, nicotinic acid, and rhabdomyolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3421570" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Lovastatin, nicotinic acid, and rhabdomyolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9915667" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : Treatment of hyperlipidemia with combined niacin-statin regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18375239" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : Safety of niacin and simvastatin combination therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18422390" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23444397" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28246253" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17192770" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19374892" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T&gt;C polymorphism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11180018" id="rid198" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>199 : Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11180018" id="rid199" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>200 : Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11583643" id="rid200" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>201 : Clinically relevant differences between the statins: implications for therapeutic selection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16581334" id="rid201" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>202 : An assessment of statin safety by nephrologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12529091" id="rid202" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>203 : Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29464863" id="rid203" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>204 : Change in ALT levels after administration of HMG-CoA reductase inhibitors to subjects with pretreatment levels three times the upper normal limit in clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29431526" id="rid204" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>205 : The potential role of statins in treating liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15131789" id="rid205" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>206 : Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16697272" id="rid206" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>207 : Incidence of statin hepatotoxicity in patients with hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17668878" id="rid207" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>208 : Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21109302" id="rid208" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>209 : Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17668874" id="rid209" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>210 : Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17240380" id="rid210" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>211 : Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19795210" id="rid211" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>212 : Statins in primary biliary cirrhosis: are they safe?</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
